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Mesenchymal stem cells (MSCs) are bone marrow derived multipotent cells with the 
ability to self-renew and differentiate into multiple connective cell lineages. In vivo, 
MSCs travel from the bone-marrow to the inflammatory sites and actively participate in 
remodeling and regeneration process under the influence of soluble growth factors. Due 
to these inherent properties, MSCs have emerged as an ideal candidate for diverse 
regenerative therapeutic applications. The development of MSC-based therapies requires 
in vitro expansion of MSCs; however, MSC expansion results in phenotypical changes 
that have limited its efficacy upon reintroduction in vivo. In order to increase the efficacy 
of MSC-based therapeutics, it is critical for us to improve the current understanding of 
MSC interactions with its niche specific factors and explore new methods to enhance 
MSC function in vivo.  
We used tumor conditioned media, which contains soluble factors secreted by 
tumor cells in culture (TCM), and inflammatory niche-specific soluble factors, such as 
platelet derived growth factor (PDGF) and transforming growth factor-β1 (TGF-β1), to 
characterize the mechanical response of MSCs. The intracellular mechanical properties of 
MSCs were dramatically altered in response to soluble factors and MSCs displayed 
cytosolic stiffening in response to TCM and TGF-β1. Although PDGF treated cells did 
not elicit any mechanical response, blocking PDGF signaling with a small molecule 
inhibitor reversed the stiffening response in TGF-β1 treated cells, indicating crosstalk 




a genome-wide microarray analysis revealed TGF-β1 dependent regulation of 
cytoskeletal actin-binding protein (ABP) genes. Actin crosslinking and bundling protein 
genes, which regulate cytosolic rheology through changes in semiflexible actin polymer 
meshworks, were upregulated with TGF-β1 treatment.  
Since TGF-β1 treatment profoundly altered the MSC phenotype after relatively 
short exposure times, we sought to understand if pretreated cells could sustain these 
enhanced characteristics leading to higher efficacy in vivo. We found that MSCs 
pretreated with TGF-β1 displayed enhanced adhesive properties while maintaining the 
expression profile of surface adhesion molecules even after removal of stimulus.  
Additionally, pretreated MSCs exposed to lineage specific induction media, demonstrated 
superior differentiation potential along multiple lineages. Based on the large number of 
sustained changes, TGF-β1 pretreated cells were used to treat full thickness skin wounds 
for in vivo wound healing model to determine their therapeutic efficacy. TGF-β1 
pretreated MSCs increased wound closure rate and displayed enhanced migration of 
MSCs towards the center of the wound compared to the control cells. 
In conclusion, MSCs with altered mechanical properties after soluble factor 
pretreatment display significantly improved cell functions leading to highly efficient 
tissue regeneration in vivo. Mechanical priming of MSCs with niche specific factors prior 









 Current strategies for healing damaged tissues rely heavily on native cell recruitment [1]. 
Biomaterials are often used to create scaffolds that mimic in vivo tissue niches. Bioactive 
factors found in these niches can then be incorporated in these scaffolds or used directly 
to promote native cell recruitment [2,3]. Acellular scaffolds and bioactive factors have 
been used successfully in tissue engineering and regenerative medicine applications; 
however, these strategies are difficult to apply in acute conditions or chronic diseases 
when native cell recruitment is more limited. Also, these treatment strategies are not 
useful in gene therapy where cells must first be engineered to correct gene defects. 
Alternatively, stem cell based therapy has been proposed to improve upon the current 
techniques and provide an exciting new platform for tissue engineering, regenerative 
medicine, and gene therapy [4-6]. Stem cells possess the ability to self-renew and 
differentiate into multiple cell lineages that play a central role in the regeneration process. 
Mesenchymal stem cells (MSCs) which differentiate into connective tissue cells are very 
attractive candidates for cell therapy in part to their natural ability to home to damaged 
tissues without eliciting an immune response [7]. The methods of delivering MSCs are 
diverse; they can be infused systemically in blood or transplanted topically and they can 
also be embedded in a scaffold, which is used to guide their migration and differentiation 
[8]. Scaffolds can be designed to mimic the native tissue structure by providing chemical 
and mechanical cues that support cell engraftment and differentiation along specific 
mesodermal lineages. In fact environmental cues present in the regenerating tissues 
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determine the fate of transplanted cells; manipulating in vivo tissue environments to 
control cell fate provides a major obstacle in the use of stem cells expanded ex vivo [9].  
In vivo, MSCs are actively recruited to sites of inflammation where they can be 
exposed to a diverse range of niche specific factors. MSCs can successfully adapt to 
environments with mechanically stringent characteristics such as cyclic stress and strain 
in damaged cartilage, coordinated contraction and relaxation of cardiac muscle in the 
heart, extremely rigid bone tissue, as well as chemically enriched networks of fibrotic 
tissues and tumors. Cells can generate force and balance intracellular tension caused by 
external forces and other biophysical stimuli in these tissue niches [10]. The mechanical 
response of a cell to chemical or physical stimuli is critical for a multitude of cellular 
processes including cell adhesion and motility, cell growth and differentiation, protein 
and DNA synthesis, and apoptosis [11,12]. A more dynamic understanding of how 
mechanical stress regulates cell function requires increased knowledge of the microscopic 
mechanical properties of cells and their extracellular environments. The intracellular 
mechanical properties of live cells are determined by the complex organization of 
cytoskeletal filamentous proteins including actin, microtubules and intermediate 
filaments, extending from the cell cortex (just below the plasma membrane) to the cell 
nucleus [13]. Chemical and physical stimuli alter cell shape and cytoskeletal organization 
by activating cytoskeletal mediators, including small Rho GTPases RhoA, Rac1, and 
Cdc42 and actin-binding proteins (ABPs), which regulate actin filament length through 
capping, branching, and severing processes. The cytoskeletal network responds 
dynamically to soluble or mechanical cues provided by the extracellular matrix (ECM) 
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and is directly connected to canonical signal transduction pathways important in tissue 
regeneration and cancer [14,15].  
Biological tissues consist of a multitude of cells organized in a scaffold of 
extracellular matrix (ECM) proteins to form specific structures important for normal 
physiology. Cells communicate in these complex tissue environments through direct cell 
contacts and paracrine signaling to maintain the balance of cell proliferation and cell 
death required for normal tissue homeostasis [16]. Although multiple studies have 
provided mechanistic insight into both microscale cell mechanics and macroscale tissue 
properties individually, the correlation between the two is far more complex and has yet 
to be elucidated [17,18]. Nonetheless, it is well established that physiological behavior of 
tissue is very much dependent upon its cellular components. Cells can mechanically 
respond to the chemical and mechanical cues present in ECM and reciprocate the 
interaction by actively remodeling the surrounding ECM. 
1.1.  THESIS OVERVIEW 
The development of stem cell based therapeutics that engraft and incorporate into 
biological tissues may expand the current limits of regenerative medicine. Although 
MSCs hold great promise as cell-based therapies, the results from clinical studies have 
been inconsistent [19-21]. In order to increase the efficacy of MSC-based therapeutics, it 
is critical for us to improve the current understanding of MSC interactions with tissue 
niche related factors and explore new methods to enhance MSC function in vivo.  
In Chapter 2, the key concepts that are essential to review the studies are briefly 
discussed. First, the properties of mesenchymal stem cells and the role of soluble factors 
in recruiting them to tissue niches are described followed by the discussion of the 
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relevant signaling pathways important in regulating MSC behavior. The intracellular 
cytoskeletal machinery that controls cell mechanics is next outlined. Finally, we conclude 
with the theory of Brownian motion and the technique of multiple particle tracking 
(MPT), which was used for the mechanical characterization of MSCs.  
In chapters 3-4, we detailed our studies on the effects of specific soluble factors 
on cytoskeletal mechanics of murine bone marrow derived mesenchymal stem cells. In 
chapter 3, tumor conditioned media, a cocktail of growth factors representing the 
chemical cues in the inflammatory tumor niche, was utilized to characterize the 
mechanical response of MSCs in comparison to fibroblasts. In chapter 4, we describe the 
effects of individual factors platelet derived growth factor (PDGF) and transforming 
growth factor-β1 (TGF-β1) on microrheology of MSCs. Although, the presence of these 
two factors in inflammatory niches and their crosstalk in cells of mesenchymal origin has 
been well-documented, their effects on the mechanical properties of individual cells 
remained poorly understood. Here, the role of the crosstalk between these two signaling 
pathways in regulating MSC behavior was elucidated. 
In chapter 5, the effects of TGF-β1 and PDGF on MSC migration and adhesion 
were examined. Cell adhesion and migration play key roles during embryonic 
development, inflammation, and tissue regeneration. These studies were essential to 
understand the role of soluble factors in regulating the interaction between MSCs and the 
ECM. 
In chapter 6, we provide a detailed genome wide microarray analysis to 
understand the effects of TGF-β1 and PDGF on transcriptional profile of MSCs. This 
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study helped us to identify key networks and molecular pathways that regulate MSC 
functions.  
In chapter 7, the sustained effects of TGF-β1 pretreatment on MSC functions, 
including, adhesion, migration, and differentiation, were examined. An in vivo punch 
biopsy full thickness skin wound model was used to determine the effects of MSC 
pretreatment on wound healing. Finally, the important findings and future directions of 
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Mesenchymal stem cells (MSCs) are multipotent progenitor cells which can be isolated 
from bone marrow (BM), expanded rapidly, and genetically modified for stable 
production of therapeutic proteins. MSCs spontaneously home to sites of inflammation 
including wounds, tumors, and regenerating tissues and subsequently integrate 
themselves in those tissue niches. Pro-inflammatory molecules secreted by tumors and 
wounds regulate the fate of MSCs incorporated in the tissues; however, their effects on 
the mechanical properties of MSCs have not been fully investigated. The studies 
presented in this thesis were focused on determining the effects of tumor conditioned 
media, which contains soluble factors secreted by tumor cells in culture, and 
inflammatory niche-specific soluble factors, such as platelet derived growth factor 
(PDGF) and transforming growth factor-β1 (TGF-β1), on the mechanical, adhesive and 
transcriptional properties of MSCs. The remainder of this chapter is devoted to outlining 
the key concepts that have been used recurrently in this thesis. 
2.1.  MESENCHYMAL STEM CELLS  
Mesenchymal stem cells (MSCs) were initially isolated from bone marrow and 
characterized as a clonal population of spindle-shaped stromal cells that were adherent 
to plastic and had a propensity to differentiate toward osteogenic lineages [1,2]. MSCs 
reside in the bone marrow and other tissues and can differentiate into connective tissue 
cells, including adipocytes, osteoblasts, chondrocytes, and smooth muscle cells (Figure 
2-1), required for tissue maintenance and repair [3,4]. MSCs have been isolated from 
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different tissue sources, including bone marrow [3], fat [5], umbilical cord [6], skin [7], 
cartilage [8], and dental pulp [9], and expanded in vitro and thus represent a population 
of multipotent stem cells available in high numbers for therapeutic use. Although MSC 
potency is more limited than embryonic stem (ES) cells, which differentiate along all 
cell lineages, MSCs are safer as a cell source, since they do not spontaneously form 
teratomas like ES cells [10,11]. MSCs have been genetically engineered to express a 
wide array of therapeutic proteins without inducing malignant transformation [12-15]. 
Additionally, MSCs secrete soluble factors important in autocrine and paracrine 
signaling and extracellular matrix proteins important in tissue remodeling [16]. In 
summary, due to their regenerative ability, immunosuppressive nature, and capacity to 
secrete chemotactic factors and extracellular matrix proteins, MSCs have been used as 
therapeutics in numerous applications, including myocardial infarction, diabetes, sepsis, 
lung disease and wound healing [17-21]. Currently, 407 clinical trials involving MSCs 
are in progress worldwide (https://clinicaltrials.gov/). Since soluble factors are used as 
modulators of cell function in this study, we next discuss the role of soluble factors in 
mediating cell signaling pathways involved in MSC recruitment and behavior.                     
2.2.  SOLUBLE GROWTH FACTORS 
Soluble growth factors are hormone like molecules which can interact with cells at both 
local and distal sites in vivo. Therefore, these factors play a prominent role in recruiting 
cells and influencing the cell fate in both normal and pathological conditions. Soluble 
growth factors, like vascular endothelial growth factor (VEGF), platelet derived growth 











Figure 2-1. Multipotent potential of mesenchymal stem cells. Mesenchymal stem cells 
can self-renew and differentiate into multiple lineages including osteoblasts, 
chondrocytes, adipocytes. Transdifferentiaiton into controversial lineages are shown by 
dashed arrows. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews 
Immunology (8.9: 726-736) by Uccelli et al., Copyright © 2008, Rights Managed by 




(SDF-1α), secreted by cells in the tumor microenvironment mediate the recruitment of 
cells directly from the bone marrow, including myeloid derived progenitors which 
establish a chronic state of inflammation in the tumor [23]. Subsequent, recruitment of 
MSCs to the tumor microenvironment is a key step in tumor growth and progression to 
metastatic disease that requires the formation of new blood vessels (angiogenesis), 
which supply nutrients to the tumor and provide potential routes for cancer cell 
dissemination. 
Platelets in wound sites and tumor cells in inflammatory niches release factors 
such as, transforming growth factor-β1 (TGF-β1) and platelet derived growth factor-BB 
(PDGF-BB) that have been recognized to play an important role in remodeling cell 
microenvironments in the tumor and the wound bed by promoting fibroblast activation, 
angiogenesis, differentiation and immunomodulation [24,25]. Here we briefly discuss 
the PDGF and TGF-β1signaling pathways before elaborating their role in controlling 
MSC behavior.  
2.2.1.  TRANSFORMING GROWTH FACTOR Β1 (TGF- Β1)  
Transforming growth factor-β1, a secreted protein of the TGF-β superfamily, plays a 
critical role in embryonic development and tissue homeostasis by regulating cell 
proliferation, differentiation, adhesion, migration and apoptosis [26, 27]. TGF-β1 binds 
with high affinity to TGF-β receptor type II where it recruits TGF-β receptor type I 
(ALK5) to form a tetrameric signaling complex [28]. Upon activation, TGF-β1 signaling 
pathways influence a myriad of cell processes through SMAD-dependent or independent 
pathways (Figure 2-2) [28]. The receptor activated SMAD protein complexes travel 








Figure 2-2. TGF-β signaling pathway. TGF-β ligand bind to its surface affinity 
receptors to induce SMAD-dependent and independent signaling cascades. Adapted by 
permission from Springer Science and Business Media, Pancreatic Cancer (pp 419-439) 





regulate the transcriptional response. Additionally, the activated TGF-β receptor 
complex on the cell surface can regulate a diverse array of signaling pathways (example: 
Rho GTPases ERK/MAPK, PI3K/AKT) by phosphorylation or direct interaction with 
the mediator proteins in a SMAD-independent manner.   
Abnormalities in TGF-β signaling contribute to tumor formation, cancer 
progression, inflammation, hypertrophic scar formation, and fibrosis [27, 30, 31]. The 
function of TGF-β1 on a cellular level is dependent on the developmental cell lineage, 
context of the interaction, and concentration [32]. The variation in TGF-β1-induced 
responses is easily illustrated in the context of cancer where TGF-β1 suppresses early 
tumor growth but promotes tumor progression and metastasis at later stages [33]. 
Inhibition of TGF-β1signaling has been investigated as a treatment for immune 
disorders [34], fibrosis, and metastatic cancer [35]. TGF-β1 can profoundly influence 
MSC differentiation into specific tumor-associated stromal cells, such as carcinoma 
associated fibroblasts (CAFs) [36, 37, 38], pericyte progenitor cells [39], or 
myofibroblasts [37, 40]. 
2.2.2.  PLATELET DERIVED GROWTH FACTOR-BB (PDGF-BB) 
PDGF is a key regulator of cell growth, proliferation, survival, and chemotaxis [41, 42]. 
PDGF interacts with PDGFR alpha (α) and beta (β) tyrosine kinase receptors that 
dimerize for activation of intracellular signaling (Figure 2-3). The PDGF-B ligand 
interacts with both PDGFR α and β but PDGF-A has a higher affinity for PDGFR-α 
[43]. The PDGF-A/PDGFRα signaling axis is vital for proliferation and lineage-
commitment of mesenchymal progenitor cells during embryogenesis and organogenesis 
[44]. In addition to these paracrine signaling processes, autocrine signaling is also 
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important in the tumor environment where it has been implicated in epithelial to 
mesenchymal transition of carcinoma cells [45].  MSCs primarily express PDGFR-β 
[46] which, with its ligand PDGF-B, plays a critical role in mediating the tropism and 
differentiation during vascular remodeling [44]. PDGF mediated migration is essential 






Figure 2-3. PDGF signaling pathway. Binding of PDGF-BB ligands to its surface 
receptors (PDGFR-β) lead to homodimerization of the receptors and intracellular signal 
transduction. PDGF signaling is important in regulating cellular processes such as 
proliferation, survival and migration. Adapted from Plesec TP. Pathology Research 
International (2011) [47]. 
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2.3.  CELL CYTOSKELETON 
Cells undergo rapid changes in shape and organization during soluble factor-mediated 
cell division and migration. During these dynamic changes, a group of cytoplasmic 
polymers mechanically support the cell structure and spatially organizes the contents of 
the cell.  This family of proteins, collectively known as cytoskeleton, consists of actin 
filaments, microtubules and intermediate filaments. Both microtubules and intermediate 
filaments contribute significantly to the organization and integrity of cells; however, 
actin cytoskeleton and its associated proteins enable cells to dynamically respond and 
adapt to the environmental cues [48]. The organization of filamentous actin, which is 
controlled by the rapid polymerization and depolymerization of globular actin, changes 
dynamically to transform cell shape and generate mechanical forces required for 
numerous cellular processes, including adhesion, migration, division, molecular 
transport, and differentiation. Small RhoGTPases and actin binding proteins control the 
organization of cytoskeletal actin by regulating assembly and disassembly of the 
filaments as well its interaction with other structural complexes like focal adhesion; 
whereas, myosin motor proteins interact with actin filaments to control actin myosin 
contractility and  cell migration.  The family of binding proteins consists of several 
classes of regulatory proteins such as polymerizing factors (example: twinfilin, profilin), 
which promote actin filament growth, nucleation and branch forming proteins (example: 
Arp2/3), which initiate new filament formation; capping proteins (example: formin, 
capZ), which abrogate filament growth; depolymerizing (example: ADF/cofilin) and 
severing factors (example: gelsolin), which dissociate the monomers from filaments; and 
bundlers(example: α-actinin, fascin), crosslinkers (example: filamin) and stabilizing 
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proteins (example: tropomyosin, calponin), which give rise to higher-order network 
structures like stress fibers (Figure 2-4) [49].  
The actin cytoskeleton is linked to the extracellular matrix or other cells via cell 
adhesion molecules (CAMs), including integrins [50] and cadherins [51]. Integrins are 
membrane-spanning cell surface receptors that play a major role in cell-matrix 
interactions. The extracellular portion of integrin glycoproteins interacts with matrix 
proteins, including fibronectin and collagen, and the intracellular domain is bound to 
integrin-actin linker protein complex (focal adhesion), formed by talin, vinculin, and α-
actinin [50]. These groups of linker proteins are very dynamic to reciprocate the force 
between cell and its niche, thus playing key role during mechanotransduction [52].  
2.4.  CELL RHEOLOGY 
The study of rheology is used to describe the flow and deformation of materials under 
applied force. Cells are considered soft biomaterials that behave as complex fluids [53, 
54]. They are viscoelastic in nature since they resist deformation at small time scales 
like an elastic solid and deform at larger time scales like a viscous fluid. The 
intracellular rheological properties of the cell are determined by the organization of 
cytoskeletal actin, which forms a mesh-like structure in the cell cytoplasm [53, 55]. 
Parallel bundles of actin filaments provide tensile strength and strong contractile 
activity; whereas, cross-linked bundles of actin filaments increase intracellular elasticity. 
Due to inherent heterogeneity in actin architecture, local rheological properties can vary 
drastically throughout the cell [56, 57]. Characterization of this heterogeneity during a 
biochemical or biophysical factor mediated event can provide new insights into the cell 












Figure 2-4. Family of Actin-binding proteins. Actin-binding proteins dynamically 
regulate growth, organization and interaction of actin with other proteins in cytoplasm 




Among the techniques available to characterize intracellular rheology [53], 
multiple particle tracking microrheology (MPTM) enables direct and rapid 
measurements to capture the short-term or transient mechanical response in a cell [58]. 
MPTM has been successfully used to map the heterogeneities in local microrheological 
properties of cells. To elaborate, injected submicron particles are embedded in the 
cytosol to probe the local microenvironment (Figure 2-5). The movement of the 
embedded particles is heavily influenced by organization of the actin meshwork and can 
be used to determine the local viscoelastic properties in the following manner [58, 59].  
Brownian motion describes the movement of a particle in a quiescent fluid, 
which is driven by the inherent thermal energy. Motion of a nanoparticle suspended in a 
purely viscous liquid remains unhindered and eventually the particle can move to a new 
location independent of the previous step. This pattern of movement resembles very well 
with the random walk model that can be used to describe the random motion of the 
embedded particle. In this scenario the particle motion is diffusive and the mean square 
displacement (MSD) of the particle varies linearly with time. When the particle is 
embedded in a viscoelastic fluid, its motion becomes more restricted (“subdiffusive”) 
due to entrapment in the surrounding structure. In this case the MSD of the nanoparticle 
varies with time at slope < < 1. To capture the viscoelastic behavior of cells, the internal 
thermal energy driven Brownian motion of the embedded nanoparticles are captured at a 
high magnification with high speed camera for relatively short time (video duration 
under a minute). For 2D tracking, x-y displacements of the tracked particles are used to 
calculate mean square displacement using the following equation: 
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The mean square displacements (MSD) of the particles are correlated to the local 










In a viscous liquid, diffusivity due to thermal energy driven motion can be 
described using Stokes-Einstein equation:  
Bk T  





where D is the diffusion coefficient, kB is Boltzmann’s constant, T is temperature, a is 
particle radius, and η is viscosity of the fluid. 
To describe viscoelastic properties of complex fluids, Mason et al derived 
complex shear modulus of the viscoelastic fluid using a modified Stokes-Einstein 
equation in the frequency domain: 
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Cells typically behave like viscous liquid (G’’>G’) at lower frequencies (or 
higher time scales) and elastic solid (G’>G’’) at large frequencies (or short time scales). 
The phase angle (δ, where δ= arctan (G’’/G’)) can be used to characterize the 
viscoelastic nature of the cell cytoplasm, where δ=90
0
 for a Newtonian viscous liquid, 
δ=0
0




 for a viscoelastic material. Individual location 
specific particles MSDs can be used to calculate local viscoelastic properties; whereas, 
all MSDs from a cell can be ensemble averaged to evaluate overall viscoelastic 
behavior. This technique uniquely allows measuring the local rheological properties in 
specific regions of the cell to determine the heterogeneity, which are not measurable by 
bulk rheological techniques. MPTM has been successfully adapted to characterize a 
great range of complex biological fluids including mucus, reconstituted actin solution 














Figure 2-5: Thematic presentation of multiple particle tracking microrheology. (A) 
dialysis of nano/micro-particle; (B) Distribution of particle on micro-carrier; (C) 
injection of particles using a ballistic particle injector (not shown) in the cells, (D) 
capturing displacement of embedded nanoparticle using fluorescence microscope and 
high speed CCD camera; (E) and (F) calculation of micro-rheological parameters using 
appropriate software. Adapted from Annual review of biophysics (38: 301-326), by 
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CHAPTER 3: DIFFERENTIAL MECHANICAL RESPONSE OF 





The progression of neoplastic malignancies is a complex process resulting not only from 
the accumulation of mutations within tumor cells, but also modulation of the tumor 
microenvironment. Recent advances have shown that the recruitment and subsequent 
heterotypic interactions between cancer cells and stromal cells including fibroblasts and 
bone marrow-derived mesenchymal stem cells (MSCs) are crucial for carcinogenesis. 
Though extensive work has been done analyzing the signals that recruit these cells, the 
governing mechanical properties have not been fully investigated. Here, we reported that 
despite their initial similarities, MSCs not only responded faster but also more 
dramatically to pro-migratory tumor-secreted soluble factors. Utilizing multiple particle 
tracking microrheology to probe the cytoskeletal mechanical properties, we showed that 
MSCs stiffen completely within one hour, three times faster than fibroblasts. In addition, 
unlike fibroblasts, MSCs exposed to tumor-secreted soluble factors displayed a 
functionally different phenotype characterized by morphological elongation, decreased 
actin stress fiber density, and decreased adhesion. These findings demonstrated a 
fundamental difference in the recruitment of fibroblasts and MSCs, knowledge necessary 
for the understanding of tumor development. Furthermore, this native homing ability of 
MSCs makes them ideal vectors for delivery of therapeutic genes directly to the tumor. 
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3.1.  INTRODUCTION 
The microenvironment in a solid tumor develops under the constant influence of 
inflammatory mediators [1]. These molecules, which include a milieu of cytokines, 
chemokines, and growth factors, are important targets for recruitment of a variety of cells 
such as leukocytes, macrophages, monocytes, fibroblasts and mesenchymal stem cells 
(MSCs) [2]. Previous literature on the MSCs and fibroblasts suggests functional 
similarity as indicated both by global gene expression [3] as well as immunosuppression 
in allogeneic transplantation[4]. In the tumor stroma both can also form activated cancer 
associated fibroblasts (CAFs) or myofibroblasts [2,5], though MSCs can additionally 
differentiate into pericyte progenitor cells (PPCs) [6]. Increased numbers of 
myofibroblasts in the wound bed and in other sites of chronic inflammation have also 
been associated with MSC progenitors [2]. Notably, both cell types also aid in tumor 
growth and metastasis via autocrine and paracrine signaling [7,8]. In light of this, recent 
studies have begun to investigate these cells not only as alternative targets for anti-cancer 
therapy [9], but also for use as targeted gene-delivery vehicles [10].  
For the latter approach, MSCs have shown greater promise than fibroblasts [11]. 
This may be in part because fibroblasts are recruited locally to form activated CAFs [12], 
whereas MSCs derived from the bone marrow must natively home through circulation to 
distal tumor sites. Consequentially, the therapeutic use of systemically infused MSCs to 
tumors has been investigated in breast [13], colon [14], ovarian carcinomas [15], gliomas 
[16], and Kaposi’s sarcomas [17]. Despite this potential, extended ex vivo culture reduces 
homing capacity of MSCs [18] and the majority of systemically infused MSCs become 
trapped in the lungs [5,19,20]. To overcome this, breast cancer cell-conditioned media 
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[7], hypoxic preconditioning [21,22], and treatment with individual chemokines or 
growth factors [23,24] have all been investigated to increase MSC mobility; however, the 
effects of inflammatory mediators on the microscopic mechanical properties of MSCs 
have not been fully elucidated. 
This study sought to understand the underlying mechanical differences in MSCs 
and fibroblasts as they migrate toward tumors. In order to best simulate the signals 
migrating cells would receive in vivo, we utilized 4T1 breast tumor cell conditioned 
media (TCM) to stimulate the cells in vitro. We found that after treatment with TCM, 
MSCs underwent an exaggerated response as compared to fibroblasts, and that this 
response could potentially be explained by altered gene expression of Rho GTPases 
Cdc42 and RhoA. We further demonstrate that even one hour incubation with TCM 
increases cell motility, indicating a novel ‘mechanical priming’ achieved by short-term 
TCM preconditioning.  
3.2.  MATERIALS AND METHODS 
Materials: Cellgro IMDM, RPMI 1640, DMEM, L-glutamine, sodium bicarbonate, PBS, 
and penicillin-streptomycin were purchased from Mediatech. FBS was purchased from 
Atlanta Biologicals and Type I, II collagenase from Worthington Biochemicals. Rat anti-
mouse PE-Sca1, PerCP-CD45, PE-CD29, and APC-CD11b, and red blood cell lysis 
buffer were purchased from Biolegend. Rhodamine-Phalloidin, rabbit vinculin 
monoclonal antibody, Alexa Fluor 488 anti-rabbit IgG, FITC-conjugated mouse anti-
alpha tubulin, and Fluospheres carboxylate-modified 100 nm particles (F8801) were 
purchased from Invitrogen. Cy3-SMA was purchased from Sigma. PDS-1000 Biolistic 
Helium Particle Injection, 1800 psi rupture discs, and macrocarriers were purchased from 
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BioRad. Primers for gene analysis were obtained from IDT. All other reagents were 
purchased from VWR or Sigma-Alrich unless otherwise specified. 
Cell Culture: Swiss 3T3 fibroblasts and 4T1 mammary carcinoma cells were purchased 
from American Type Cell Culture and cultured according to manufacturer's protocol. 
MSCs were isolated from murine bone marrow and cultured in MSC growth media 
(IMDM supplemented with 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 
U/ml streptomycin). Bone marrow was extracted from the femurs and tibias of 8–10 
week old Balb/C mice (Charles River Laboratories, Wilmington, MA) by crushing the 
bones in FBS solution (1 mg/ml Type I collagenase in 30% FBS and 70% PBS), filtering 
the cell suspension using a 70-µm cell strainer, and centrifuging at 2000× g for 10 





. After 24 hours, non-adherent cells were removed, and cells were 
cultured in MSC growth media (replaced 3 times per week). Differentiation was induced 
with either adipogenic or osteogenic media per standard protocols. All animal studies 
were approved by the Institutional Animal Care and Use Committee at Georgia Institute 
of Technology. 
Flow Cytometry: To determine cell phenotype, cells were analyzed with a LSR-II flow 
cytometer. Briefly, cells were detached, centrifuged, and separated into 100 µl aliquots 
then labeled with either 2% PerCP-CD45, PE-Sca1, and APC-CD11b antibodies or PE-
CD61, FITC-CD29, and APC-VCAM1. A negative control for each cell type was used to 
determine positive populations. All studies were performed in triplicate with n = 100,000 
events per sample. 
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Conditioned Media Collection: Murine mammary carcinoma 4T1 cells were cultured to 
confluency in 10 cm dishes with standard growth media, then washed in PBS, and 
incubated in 8 mL unsupplemented DMEM for 24 hours. Cell-free TCM was obtained by 
centrifugation and filtration. TCM was prepared in a single batch, aliquoted and frozen at 
−80°C for future use. For all assays with TCM, control media was unsupplemented 
DMEM. 
Microrheological Characterization: Intracellular mechanical properties of living cells 
were determined by multiple particle tracking microrheology (MPTM), as previously 
described [25]. Briefly, 100 nm probe particles were injected into the cytosol of MSCs 
using PDS-1000 Biolistic Helium Particle Injection System (Biorad). The thermal motion 
of these probes is directly related directly to local rheological properties via the Stokes-
Einstein equation [26]. High spatiotemporal resolution videos of injected cells were 
collected with a Nikon CFI Apochromat TIRF 100X oil-immersion lens (NA=1.49) on a 
Nikon Eclipse Ti inverted epifluorescent microscope maintained at 37° C and 5% carbon 
dioxide. A custom MPT routine incorporated in the MetaMorph software (Molecular 
Devices; Downington, PA) was then used to simultaneously monitor the coordinates of 5-
20 particles per video. For each condition, particles were tracked in a minimum of 10 
cells per condition. Time-dependent individual particle mean square displacements 
(MSDs) were ensemble-averaged and used to determine the average frequency dependent 
elastic moduli (G’), viscous moduli (G’’) and phase angle (δ), which were reported in this 
study. 
Immunoflourescence Assays: For visualization of cytoskeletal proteins, cells cultured 
on glass cover slips were briefly extracted in a buffer containing 80 mM PIPES (pH 6.8), 
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1 mM MgCl2, 5 mM EDTA, and 0.5% Triton X-100 before fixation with 0.5% 
glutaraldehyde in PBS. The reaction was quenched with 1 mg/mL sodium borohydride, 
before permeabilization with Triton X-100 and blocking with FBS. Cells were stained for 
one hour at room temperature with either 1:50 FITC-conjugated anti-tubulin, 1:200 
Rhodamine Phalloidin , or 1 µg/mL rabbit anti-vinculin followed by 1:1000 goat anti-
rabbit Alexa Flour 488 before sealing with Vectashield (Vector Labs) containing DAPI. 
For morphological visualization, cells were stained with crystal violet then rinsed 
extensively. All cells were visualized using either an inverted Nikon Eclipse Ti or Zeiss 
LSM 510 UV confocal microscope. 
Quantitative Image Analysis: Quantitative image analysis was performed by a series of 
custom written MATLAB algorithms. For cell elongation, borders were manually drawn 
around cells before segmentation to extract cell major and minor axis. After 
normalization for background, stress fibers were segmented by a Laplacian filter, and 
then normalized to cell area extracted from a built-in MATLAB thresholding algorithm. 
Nuclei were analyzed using a semi-automated MATLAB algorithm that visualized each 
image before quantification to ensure only single nuclei were measured. Similarly, for 
actin and vinculin quantification, images were normalized then segmented for 
quantification. 
Gene Expression Analysis: Total RNA was isolated using TRIzol reagent (Invitrogen) 
per manufacturer's protocol before reverse transcription using the iScript cDNA synthesis 
kit (BioRad). DNA concentration and quality were verified by spectroscopy. To verify 
differentiation, PCR was run per previous literature. For qRT-PCR on the small Rho 
GTPases, Cdc42, RhoA, and Rac1, as well as an endogenous GAPDH control, the real-
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time PCR reaction was run using SsoAdvanced SYBR Green Supermix (BioRad) in an 
AB Step One Plus thermocycler (n = 5). Primer sequences are reported in Appendix 1 
(Table A-1). Values are reported as fold change in expression over fibroblasts in CM ± 
S.E.M. after normalization to respective endogenous GAPDH control. 
Statistics: All studies were performed in triplicate (unless otherwise indicated). 
Statistical analysis was carried out using a student's t-test for comparison between two 
groups or analysis of variance (ANOVA) to compare effects between cell types, 
considering p<0.05 to be significant (***p<0.001,**p<0.01,*p<0.05). Data were reported 
as the mean ± s.e.m. 
3.3.  RESULTS  
Characterization of Bone Marrow Derived MSCs: To verify the phenotype of MSCs, 
cells were assayed for both cell surface marker expression and differentiation capacity. 
After purification by adherence to plastic, MSCs were negative for myeloid and 
hematopoietic stem cell markers CD11b and CD45 and positive for Sca1, CD29, CD61, 
and VCAM1 (Figure 3-1). Fibroblast expression is provided for comparison (Figure 1A, 
Right). Osteogenesis and adipogenesis were induced in passage 4 MSCs using standard 
protocols [27]. After 4 weeks incubation in adipogenic and osteogenic media, MSCs 
differentiated into adipocytes (Figure 3-2A) and osteoblasts (Figure 3-2B) respectively, 





Figure 3-1. Characterization of bone marrow isolated MSCs and fibroblasts. 
Phenotypic analysis was performed by flow cytometry on adherent bone marrow cells 










Morphological Changes after Incubation with Tumor Cell-Secreted Soluble Factors: 
To investigate the response of MSCs to tumor cell-conditioned media (TCM), cells were 
incubated in serum-free TCM or control media (CM) for 24 hours. MSCs underwent a 
morphological change from a cobblestone appearance to an elongated phenotype (Figure 
3-3A-B). In comparison, Swiss 3T3 fibroblasts (Figure 3-3C-D) and primary isolated 
kidney fibroblasts (Figure 3-3E-F) had similar initial morphologies, but did not undergo a 
morphological change upon treatment with TCM.  
Figure 3-2. Multilineage differentiation potential of MSCs. Purified MSCs differentiated 
into adipocytes (A) and osteoblasts (B) within 3 weeks in lineage-specific differentiation 
media as shown by staining. Adipocytes and osteoblasts were stained with oil red o and 






Figure 3-3. Tumor-secreted soluble factors alter MSC morphology. Brightfield 
images of (A-B) primary fibroblasts (isolated from Balb/C mouse kidney), (C-D) 
Swiss 3T3 fibroblasts, and (E-F) murine MSCs (isolated from Balb/C mouse bone 
marrow) incubated for 24 hours in control media (CM, top) or tumor cell-
conditioned media (TCM, bottom), then fixed in methanol, and stained with 
crystal violet. MSCs elongated dramatically in response to TCM (E-F); whereas, 
primary (A-B) and immortalized (C-D) fibroblasts did not respond to TCM 
treatment. (Scale bar = 100 µm) 
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Cytoskeletal Changes after TCM Treatment: We next examined the changes in 
cytoskeletal arrangement necessary to produce the elongated phenotype. To accomplish 
this, CM and TCM treated cells were fixed and stained for filamentous actin, 
microtubules, and nuclei (Figure 3-4). Cytoskeletal parameters were quantified from 
maximum intensity projections of confocal image stacks (3 images per stack) using a 
custom-written MATLAB algorithm. First, the cell elongation factor was quantified using 
a ratio of the minor to major cell axis (Figure 3-5A). For control MSCs and 3T3 
fibroblasts, the cell shape factors were near unity, indicating similarity in their native cell 
shape. In the presence of TCM, MSCs elongated by ~30% after 12 hours (p<0.05) and 
~75% after 24 hours (p<0.001); whereas, the elongation factor of 3T3 fibroblasts 
remained near unity. We then quantified the stress fiber factor, which is the density of 
stress fibers normalized to cell area (Figure 3-5B). The stress fiber factor of TCM-treated 
3T3 fibroblasts remained constant; whereas, the stress fiber factor of MSCs was reduced 
more than 25% within 12 hours. Though this could in part be due to control cells being 
flatter than TCM treated cells, the use of maximum intensity projections minimizes this 
possibility, suggesting the changes are in fact due to decreases in actin stress fiber 
density. Upon stimulation with TCM, the nuclei of MSCs elongated dramatically (Figure 
3-4). A nuclear shape factor was used to characterize nuclear elongation (Figure 3-5C), 
with a value of one indicating the nucleus is perfectly round. Initially, MSCs and 3T3 
fibroblasts had nuclear shape factors of approximately 0.75; however, upon incubation 
with TCM for 12 hours, MSC nuclei were elongated by approximately 13% (Figure 3-
5C). Nuclear elongation was never seen in 3T3 fibroblasts and no further elongation was 









Figure 3-4. MSCs reorganize their cytoskeleton in response to tumor-secreted soluble 
factors. Confocal images of CM and TCM-treated MSCs (A-C) and 3T3 fibroblasts (D-
E) stained with Phalloidin (F-actin, red), anti-α-tubulin (microtubules, green), and DAPI 
(nucleus, blue).  The shape and cytoskeletal organization of CM-treated MSCs (A) and 
CM- (D) and TCM- (E) treated Swiss 3T3 fibroblasts were similar (24 hours after CM or 
TCM addition); whereas, TCM-treated MSCs were elongated with extended cytoskeletal 
filaments (B-C). MSC elongation increased between 12- (B) and 24- (C) hours, indicating 




Figure 3-5. Cytoskeletal parameters were determined by analysis of confocal images 
with a custom MATLAB routine. The cell (A) and nuclear (C) shape factors were used to 
characterize the circularity of an elliptical outline of the cell or nucleus, respectively, with 
a shape factor of 1 indicating a perfect circle. The stress fiber factor (B) was used to 
characterize the density of actin stress fibers per cell area. Cytoskeletal changes observed 
in TCM-treated MSCs (Figure 3-4B-C) were confirmed using the cytoskeletal parameters 




TCM Alters the Distribution and Strength of MSC Focal Adhesions: The 
cytoskeleton is linked to the extracellular environment via focal adhesion complexes, 
which are important regulators of cell motility. To determine the effects of TCM on cell 
adhesion, control and TCM-treated MSCs and 3T3 fibroblasts (treated for 24 hours) were 
fixed and stained with FITC anti-vinculin, a focal adhesion marker, and Rhodamine-
Phalloidin, which stains filamentous actin (Figure 3-6, Figure 3-7). TCM treatment 
dramatically affected the overall number and morphology of focal adhesions on MSCs 
(Figure 3-6, Figure 3-7); however, it had no apparent effect on 3T3 fibroblast focal 
adhesions (Figure 3-6). For MSCs, the ratio of vinculin to actin was quantified from 
confocal images using a MATLAB routine (Figure 3-7B). Twenty-four hours after TCM 
addition the vinculin to actin ratio was reduced by 50% (Figure 3-7B) and focal 
adhesions no longer displayed their characteristic brush-like pattern (Figure 3-6) but were 
instead localized at the tips of elongated cells (Figure 3-6, Figure 3-7).  
Cytoskeletal Stiffening in Response to TCM: MPT was used to characterize the 
immediate effects of TCM (30 minutes to 3 hours) on the intracellular mechanical 
properties of MSCs (Figure 3-8A, Figure 3-9A–E) and 3T3 fibroblasts (Figure 3-
8B, Figure 3-9F–J). Corresponding morphological changes were not seen in 
immunostained fixed MSCs until 12–24 hours after TCM treatment and were never seen 
in 3T3 fibroblasts (Figure 3-4). For MPT studies, 100 nm probe particles, with diameters 
more than 100-fold smaller than the cells, were injected into the cytoplasm (Figure 3-8C), 
and their mobility, characterized by the <<Δr
2
(Δt)>> (Figure 3-8A–B), was used to 
determine intracellular rheology. Initially, the amplitude and logarithmic slope of the 
<<Δr
2
(Δt)>> for MSCs and 3T3 fibroblasts were comparable, indicating similarity in 
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their microscopic mechanical properties (Figure 3-9A,F). Within 30 minutes, TCM 
treatment reduced the <<Δr
2
(Δt)>> for MSCs up to 20-fold; however, similar changes 







Figure 3-6. Epifluorescent microscopy was used to further investigate the effect of 
TCM on focal adhesion distribution in MSCs and 3T3 fibroblasts. CM-treated 
MSCs displayed a brush-like pattern of focal adhesions; whereas, focal adhesion 
on TCM-treated cells appeared as points at the end of cytoskeletal 
extensions.TCM-treatment had no effect on the pattern of focal adhesions on 3T3 







Figure 3-7. Changes in the distribution of focal adhesions. (A) Confocal 
micrographs of 24-hour CM- (left) and TCM- (right) treated MSCs stained with 
Phalloidin (F-actin, red), and anti-vinculin (green). (B) The vinculin to actin ratios 
quantified from confocal images demonstrated a reduced concentration of focal 







Figure 3-8. Multiple particle tracking microrheology. The ensemble averaged mean 
squared displacements (<<r
2
(∆t)>>) of 100 nm particles embedded in the cytoplasm of 
TCM-treated MSCs (A) and 3T3 fibroblasts (B) were evaluated from 0-3 hours. For both 
cell lines, treatment with TCM reduced the rate of cytoplasmic particle transport in a 
time-dependent manner. Fluorescent image of 100 nm particles (green) in the cytoplasm 
of a MSC, which was fixed and stained with phalloidin (red) and DAPI (blue) (C). The 
phase angle, δ = arctan (G”(ω))/ G’(ω)), was used to characterize the viscoelastic nature  
of the cytoplasm over the course of the experiment (D). The viscoelastic nature of MSCs 
and 3T3 fibroblasts were similar initially and 3 hours after TCM-treatment; however, 
MSCs responded much more rapidly to TCM with a 4-fold reduction in δ within 60 
minutes. (scale bar = 10µm) 
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The ratio of viscous to elastic character, or phase angle (δ), of control cells was 
55°<δ<70°, indicating that initially the cytoplasm behaved more like a viscous liquid than 
an elastic solid. One hour after TCM treatment, the cytoplasm of MSCs had dramatically 
stiffened with 10°<δ<15°. This effect was not seen in 3T3 fibroblasts until 3 hours after 
TCM treatment. MPTM was also used to quantify the rheological properties of the 
cytoplasm, which is highly viscoelastic in part to its crowded nature. The frequency-
dependent viscoelasticity of MSCs changed dramatically after TCM treatment (Figure 3-




TCM Rapidly Increases In vitro Cell Migration: Previous studies documented 
increased MSC migration toward chemotactic factors after 18-24 hours [23,24,28]. Our 
multiple particle tracking studies revealed dramatic changes in intracellular mechanics 
within 1 hour. To determine if these mechanical changes were correlated with increased 
mobility, the migration of control and treated cells toward CM or TCM was measured 
hourly for 3 hours using transwell inserts with 3µm (Figure 3-10A) or 8µm (Figure 3-
10B) pores. Without chemotactic factors present, few MSCs and 3T3 fibroblasts migrated 
through 3µm pores; however, when TCM was added, there was a significant increase in 
MSC migration within 3 hours (p<0.01, Figure 3-10A). MSC migration through 8µm 





Figure 3-9. TCM alters cytoplasmic rheology. The time-dependent ensemble averaged 
MSDs of 100 nm particles embedded in the cytoplasm of MSCs and 3T3 fibroblasts 
were converted to frequency-dependent elastic (G’, solid lines) and visous (G”, dashed 
lines) moduli using a custom algorithm written for Matlab software. The ensemble-
averaged frequency-dependent viscoelasticities of MSCs (A-E, left) and 3T3 
fibroblasts (F-J, right) prior to (A,F) and 30 minutes (B,G), 1 hour (C,H), 2 hours 
(D,I), or 3 hours (E,J) after treatment with TCM. The cytoplasm of MSCs became 
predominantly elastic within 60 minutes; whereas, 3T3 fibroblasts required 3 hours to 
undergo a similar change. 
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MSCs also responded more rapidly to TCM, with increased MSC migration within 2 
hours (p<0.001) and increased 3T3 fibroblast migration within 3 hours (p<0.01). To 
determine if mechanical changes exhibited by MSCs in the first hour were indicative of a 
more migratory phenotype, we pre-treated both cell types for one hour with TCM before 
seeding in 8µm transwell inserts. Pre-treatment with TCM increased MSC and 3T3 
fibroblast migration toward CM and TCM, though more significantly toward TCM 
(Figure 3-10C). Statistical analysis also revealed synergistic effects of TCM pre-
treatment and migration toward TCM for both cell types, suggesting that not only does 
pre-treatment increase motility but also causes a preferential migration towards 
chemotactic gradients. 
Changes in Gene Expression Associated with Altered Mechanical Response: To 
understand genotypic changes resulting in altered mechanical responses, we performed 
qRT-PCR to investigate the expression of the Rho GTPases RhoA, Rac1, and Cdc42 that 
modulate the actin cytoskeleton (Figure 3-11A). We found that after TCM treatment, 
both cell types express significantly more Rac1 (p<0.05) as compared to their respective 
controls. Furthermore, ANOVA revealed that MSCs expressed significantly more RhoA 
overall (p<0.0001). Moreover, it showed a significant interaction effect between cell type 
and TCM treatment for Cdc42 (p<0.005), suggesting that this molecule is largely 




Figure 3-10. Effect of TCM on Cell Migration. Tranwell assays were used to 
measure the migration of MSCs and 3T3 fibroblasts through 3 µm- (A) and 8 µm- 
(B) pore transwell inserts toward CM or TCM. The average number of cells per 
image (n=9), collected with a 10x-objective, was reported. TCM significantly 
increased MSC migration, compared to CM, through 3 µm pores within 3 hours 
and 8 µm pores within 2 hours; however, fibroblast migration was only increased 
through 8 µm pores within 3 hours. MSCs and 3T3 fibroblasts were then treated 
with CM or TCM for 1 hour and allowed to migrate through 8 µm-pore transwell 
inserts toward CM or TCM for 3 hours (C). Pre-treatment with TCM resulted in 




Figure 3-11. Alterations in Gene Expression. (A) Changes in expression of small Rho 
GTPases RhoA, Rac1, and Cdc42 before and after prolonged treatment with TCM. (B) 
After 24 hour exposure to TCM, alterations in morphology and adhesion can be 
explained by differential gene expression in MSCs and fibroblasts. 
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3.4.  DISCUSSION 
In this study, TCM isolated from 4T1 metastatic breast cancer cells was used to mimic 
the chemotactic factors released by tumors. Previous studies have demonstrated that 
TCM is a potent pro-migratory cocktail of growth factors and chemokines [28,29]. 
Literature on 4T1 tumor cell conditioned media shows that it contains soluble growth 
factors including platelet-derived growth factor (PDGF), transforming growth factor 
(TGF-β1), and vascular endothelial growth factor (VEGF) [30], as well as cytokines, 
chemokines, acute phase proteins and preoteases. In two separate studies [31,32], 
researchers examined the gene expression profile of 4T1 tumor cells  in comparison to 
less metastatic cell lines, finding a variety of up-regulated pro-migratory soluble factors 
including: (a) growth factors angiopoietin 2, VEGF-C, insulin-like growth factor 2,   (b) 
chemokines CCL5, CCL7, CXCL1, CXCL16, CSF2, CSF3, (c) interleukins 1α and 23, 
and (d) matrix metalloproteases 13,3,9. It is noted this list is not comprehensive, as the 
complexity of TCM continues to yield novel pro-migratory soluble factors [29] in 
addition to unique miRNA secretomes [33]. 
Some of these growth factors, such as PDGF, TGF- β1, and VEGF, have been 
shown to directly induce mechanical and migratory changes in MSCs and fibroblasts 
[23,24,28,34-36]. However, the effects of other soluble factors present in TCM are often 
much more difficult to determine. Menon et al found that MSC exposure to tumor cell 
conditioned media up-regulates mRNA levels of 104 genes, including genes for stromal 
cell-derived factor 1 (SDF-1/CXCL12), monocyte chemotactic protein 1 (MCP-1/CCL2), 
and growth-regulated protein β (Gro-β/CXCL2), which are all potent chemokines that act 
in an autocrine fashion to further stimulate MSC migration [28]. In the same study, 
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Menon et al also found that TCM altered the organization of cytoskeletal actin, resulting 
in increased polarity and directional migration [28]. In another study, soluble factors 
(identified as extracellular matrix peptides) in LLC1 tumor cell conditioned media 
induced bone marrow derived cell secretion of pro-inflammatory cytokines, including IL-
1β, IL-6, and tumor necrosis factor α (TNF-α); whereas, serum-free media and 3T3 
conditioned media had no effect on cytokine production [37]. In contrast, tumor cells 
exchange paracrine signals with normal fibroblasts, which have been shown to promote 
matrix remodeling and tumor cell invasiveness [34].  One way this occurs is through 
tumor cell secretion of IL-1, basic fibroblast growth factor (bFGF/ FGF-2), PDGF, and/or 
TGF-β, which induce hepatocyte growth factor (HGF) secretion from fibroblasts. HGF 
then binds with its cognate receptor, c-MET, which is expressed by normal and cancer 
stem cells [38]. The HGF/c-MET signaling pathway triggers cell growth and 
angiogenesis, which are important mechanisms of cancer development, normal growth, 
and wound healing [34]. 
We hypothesize that several of the growth factors and chemokines in TCM, such 
as VEGF, PDGF, TGF- β1, directly stimulate changes in MSCs and fibroblasts; however, 
other factors in TCM, such as IL-1β, colony-stimulating factor (CSF), and TNF-α are 
more potent mediators of changes in MSCs due to autocrine signaling pathways including 
SDF-1, MCP-1, and Gro-β, which they activate rapidly. Interestingly, a more detailed 
analysis of MSC migration to individual growth factors and chemokines found that TNF-
α stimulation was necessary for MSC migration towards all chemokines tested, but had 
little effect on the migration of MSCs toward growth factors. Due to the complicated 
nature of the autocrine and paracrine signaling pathways involved in the recruitment of 
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cells to tumors, we focused our study on characterizing the effects of a cocktail of these 
factors in TCM on MSC and fibroblast behavior. 
The molecular response of MSCs to various soluble factors has been well 
characterized, but the mechanical properties that govern their migration are yet to be fully 
investigated. MPTM was used to analyze the real-time changes in live-cell mechanics. 
Previous MPT studies have demonstrated that fibroblasts stiffen both during migration 
and in response to activation of RhoA, Cdc42, or Rac1, with the largest response to RhoA 
[35,39]. This technique revealed cytoskeletal stiffening after TCM treatment larger than 
previously documented, completely changing the intracellular mechanical phenotype, 
three-fold faster in MSCs (Figure 3-8, 9). 
Analysis of expression of RhoA in untreated MSCs and fibroblasts reveals two-
fold higher expression in MSCs (Figure 3-11A), which could account for more rapid 
cytoskeletal stiffening of MSCs. RhoA can act by Rho Kinase (ROCK) to induce stress 
fiber formation and focal adhesions or to crosslink actin filaments via its downstream 
effector α-actinin [40]. In MSCs, inhibition of ROCK has been shown to increase cell 
motility, an effect which is increased in presence of the RhoA activator lysophosphatidic 
acid (LPA) [41]. In fibroblasts, equivalent stiffening to that induced by TCM was found 
by inhibition of ROCK before RhoA activation [39]. Moreover, this increase in elastic 
character is in good agreement with in vitro experiments analyzing actin polymerization 
and crosslinking dynamics [42]. A simplified schematic of this process can be seen 
in Figure 3-12. 
Transwell migration assays further illustrated how crucial this stiffening was for 
chemotaxis, as significant migration to TCM over control media was not achieved until 
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the time point after cells had transitioned to a primarily elastic phenotype (Figure 3-10B). 
Additionally, in vitro migration assays show that even a one hour exposure to TCM 
increases MSC migration. Since soluble factors mediate cell migration by interacting 
with cell surface receptors that require much longer synthesis and transport times [43], 








Figure 3-12. A simplified diagram of short-term response of cells to treatment 
with TCM by actin polymerization and crosslinking. 
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Initially, the morphology of fibroblasts and MSCs was similar; however, after 
prolonged TCM treatment, MSCs acquired an elongated spindle-shape morphology, and 
3T3 and primary fibroblasts maintained their original shape (Figure 3-3C–F). This 
morphological change in MSCs coincided with the extension of linear actin filaments and 
microtubules (Figure 3-4). These changes further support the importance of RhoA, as 
activation of Rho effector mDia1 induces cell elongation coupled with parallel alignment 
of linear actin and microtubules [44]. 
The prolonged exposure of MSCs to TCM also resulted in visible loss of stress 
fibers (Figure 3-5B) and focal adhesions (Figure 3-6, Figure 3-7). These changes 
correlate with increased expression of Cdc42, which can block Rho-induced focal 
adhesions and stress fibers [45]. Furthermore, Cdc42 is crucial in cell elongation 
processes, such as neurite outgrowth [46]. ANOVA revealed that only Cdc42 shows a 
significant interaction effect between cell type and treatment, suggesting it is a primary 
contributor to the long-term differences. 
Two unique obstacles in MSC homing as compared to fibroblasts include 
extravasation from the bone marrow to enter circulation and intravasation into the site of 
inflammation [47]. The differential cellular elongation could aid as cells squeeze through 
the basement membrane. Since undifferentiated MSCs have a more deformable nucleus, 
they are better suited for this task [48]. Our results indicate that MSC nuclei elongate in 
response to TCM (Figure 3-5C). The up-regulation of Cdc42 may also prove beneficial in 
this process, as it is critical for nuclear translocation [49]. 
These results elucidate a fundamental difference in the recruitment of fibroblasts 
and MSCs to tumors by utilizing a unique set of mechanical changes to overcome their 
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extensive physiological barriers. Furthermore, this new knowledge may be used in the 
development of novel therapeutics. Understanding the mechanisms of MSC homing can 
be used for more successful tumor targeting. Further studies can be focused on 
discovering the complex interactions of Rho GTPases and their effectors which modulate 
these cell-specific mechanical changes. 
3.5.  CONCLUSIONS 
Tumor cells recruit both MSCs and fibroblasts to the tumor microenvironment by 
secreting pro-migratory soluble factors. Both these cell types have been investigated as a 
drug delivery vehicle to transport anti-cancer therapeutics to the tumor milieu. This study 
indicates that MSCs are more rapidly responsive to tumor secreted soluble factors leading 
dramatic changes in cell shape and rheology, and increased directed migration.  This 
study suggests that MSCs may be more efficient tool for cell based cancer therapeutics 
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CHAPTER 4: MECHANICAL RESPONSE OF MESENCHYMAL 
STEM CELLS TO TRANSFORMING GROWTH FACTOR-β1 




Mesenchymal stem cells (MSCs) play an important role in matrix remodeling, fibroblast 
activation, angiogenesis, and immunomodulation and are an integral part of fibrovascular 
networks that form in developing tissues and tumors. The engraftment and function of 
MSCs in tissue niches is regulated by a multitude of soluble proteins. Transforming 
growth factor-β1 (TGF-β1) and platelet derived growth factor-BB (PDGF-BB) have 
previously been recognized for their role in MSC biology; thus, we sought to investigate 
their function in mediating MSC mechanics. Cytoskeletal organization, characterized by 
cell elongation, stress fiber formation, and condensation of actin and microtubules, was 
dramatically affected by TGF-β1, individually and in combination with PDGF. The 
intracellular mechanical response to these stimuli was measured with particle tracking 
microrheology. MSCs stiffened in response to TGF-β1 (their elastic moduli was 9-fold 
higher than control cells), a result which was enhanced by the addition of PDGF (100-
fold change). These findings will provide a more mechanistic insight for modeling tissue 
level rigidity in fibrotic tissues and tumors. 
4.1.  INTRODUCTION 
Earlier work has shown that both murine [1] and human [2] MSCs undergo dramatic 
cytoskeletal stiffening in response to the cocktail of pro-migratory molecules released by 
tumor cells. The degree of stiffening was shown to be a key differentiating factor 
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between MSCs and their less migratory fibroblast counterparts [1, 3] and even predictive 
of decreased MSC function in vivo [4]. Tumor cell-conditioned media regulates MSC 
survival, migration, proliferation and differentiation in a paracrine fashion or by 
triggering the release of other soluble factors that act through autocrine signaling 
pathways [3, 4]. Both platelet-derived growth factor-BB (PDGF-BB) and transforming 
growth factor-β1 (TGF-β1) are released by tumor cells and play important roles in 
recruiting MSCs to target sites and influencing their growth and regenerative capacity [5-
7]. 
This study sought to understand the mechanical and chemical response of MSCs 
to TGF-β1 and PDGF-BB (referred as PDGF). MSCs interact with both these factors in 
many in vivo regenerative niches as well as wound tissues and tumor. In vitro cell 
mechanics studies have thus far focused on external biophysical cues [8] or combination 
of chemical cues to induce differentiation [9]. Examining the mechanical response of 
MSCs to individual factors can provide better understanding of their role as stromal cells 
(for example, functional role in tissue remodeling, cell recruitment) during initial stages 
in wound and tumor development.  MSCs treated with TGF-β1 alone or in combination 
with PDGF exhibited dramatic elongation, condensed actin-microtubule structure and a 
highly elastic cytoplasm. Although this mechano-physical response was primarily in part 
to TGF-β1, combination of PDGF with TGF-β1 enhanced the TGF-β1 driven changes 
significantly.  
4.2.  MATERIALS AND METHODS 
Materials: IMDM, DMEM, L-glutamine, penicillin-streptomycin and trypsin were 
purchased from Mediatech and fetal bovine serum (FBS) was purchased from Atlanta 
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Biologicals. Recombinant human proteins TGF-β1 and PDGF-BB and antibodies for 
flow cytometry experiments were purchased from Biolegend. Rhodamine-Phalloidin, 
FITC-conjugated mouse anti-α-tubulin, and Fluospheres carboxylate-modified 100 nm 
particles (F8801) were purchased from Invitrogen. All other reagents were purchased 
from VWR unless otherwise specified. 
MSC isolation and culture: Murine MSCs were isolated from the bone marrow of 6-10 
weeks old adult male Balb/C mice (Charles River Laboratories, Wilmington, MA) and 
cultured in normal growth media (IMDM media supplemented with 20% FBS, 2 mM L-
glutamine, 100U/ml penicillin, and 100U/ml streptomycin). Briefly, tibiae and femurs of 
the mice were extracted and crushed in FBS. Cold PBS and collagenase I (2mg/ml) 
solutions were added subsequently to facilitate cell extraction from bone with minimal 
cell damage. Finally, the solution mixture was filtered (70 µm cell strainer) and 
centrifuged (1000xg for 10 minutes) to recover the bone marrow cell population in pellet 
form. Media was supplanted regularly to remove non-adherent BM cell populations. 
Once the adherent cells reached 80-90% confluency, the cell culture was expanded and 
subsequently purified using EasySep™ Mouse SCA1 Positive Selection Kit (StemCell 
Technologies). Purified MSCs between passages 2-6 were used for all studies.  
Soluble factor treatment: Soluble factor dilutions were prepared in serum-free DMEM 
or IMDM immediately before use. Measured values of serum and plasma PDGF and 
TGF-β1 concentrations in mice and humans vary from 0.1-100 ng/ml [10-14], with the 
majority of these values being in the range of 1-10 ng/ml. This concentration range of 
PDGF and TGF-β1 has been used in numerous in vitro cell studies [15, 16]; after 
screening the cell response across this concentration range, 5 ng/ml of PDGF and TGF-β1 
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was used in our studies. All experiments were carried out with four conditions: serum-
free control media, 5ng/ml PDGF, 5ng/ml TGF-β1 and combination of PDGF and TGF-
β1- each 5ng/ml.  MSCs were treated for 24 hours unless otherwise specified.  
Morphological analysis: Cells were fixed and stained with crystal violet and imaged 
with stereoscope microscope and Motic camera. Cell borders were traced manually and 
cell shape factors, defined as 4*π*Area/ (Perimeter) 
2
, were determined using Image J.  
Immunofluorescence staining:  To visualize cytoskeletal proteins, MSCs were cultured 
and treated on glass cover-slips in 24-well plates. Twenty four hours after soluble factor 
treatment, cells glass cover slips were briefly extracted in a buffer containing 80 mM 
PIPES (pH 6.8), 1 mM MgCl2, 5 mM EDTA, and 0.5% Triton X-100 before fixation 
with 0.5% glutaraldehyde in PBS. The reaction was quenched with 1 mg/mL sodium 
borohydride, before permeabilization with Triton X-100 and blocking with normal horse 
serum. Cells were stained for one hour at room temperature with either 1:50 FITC-
conjugated anti-tubulin, 1:200 Rhodamine Phalloidin, before sealing with Vectashield 
(Vector Labs) containing DAPI. Cells were imaged with an inverted Zeiss LSM 510 UV 
confocal microscope. Nuclear elongation factor was determined by segmenting out nuclei 
using Otsu’s method after background subtraction, and then was defined as 4•π•A/P², 
where A is the area of the nucleus and P is the perimeter of the nucleus. To segment out 
actin stress fibers, background-subtracted images were convolved with a Laplacian of 
Gaussian filter to isolated fiber-like features. After segmentation, sequential image 
dilation and erosion using a linear structuring element with varying degrees of rotation 
was used to join any disconnected stress fibers and erode any small regions produced by 
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image noise. All image analysis was performed in custom-written MATLAB algorithms 
[1]. 
Live-Cell Microrheology: Intracellular mechanical properties of living cells were 
determined by multiple particle tracking microrheology (MPTM), as previously described 
[3,4]. Briefly, 100 nm probe particles were injected into the cytosol of MSCs using PDS-
1000 Biolistic Helium Particle Injection System (Biorad). The thermal motions of these 
probes are directly related to the local rheological properties via the Stokes-Einstein 
equation. High spatiotemporal resolution videos of injected cells were collected with a 
Nikon CFI Apochromat TIRF 100X oil-immersion lens (NA=1.49) on a Nikon Eclipse Ti 
inverted epifluorescent microscope maintained at 37° C and 5% carbon dioxide. A 
custom MPT routine incorporated in the MetaMorph software (Molecular Devices; 
Downington, PA) was then used to simultaneously monitor the coordinates of 5-20 
particles per video. For each condition, particles were tracked in a minimum of 10 cells 
per condition. Time-dependent individual particle mean square displacements (MSDs) 
were ensemble-averaged and used to determine the average frequency dependent elastic 
moduli (G’), viscous moduli (G’’) and phase angle (δ), which were reported in this study. 
Flow cytometry: MSCs were analyzed with a BD LSR-II flow cytometer to capture the 
effects of soluble factor treatment on cell surface markers. Briefly, both treated and 
untreated cells were detached from 10 cm dishes, centrifuged, and suspended in 100 µl 
cold FACS buffer (2% FBS, 1mM EDTA in PBS). Cells were then incubated with APC-
CD140b/PDGFR-β (1:20). To quantify PDGFR-β expression after 1 hour, cells were 
primarily incubated with biotin conjugated anti-mouse CD140b and subsequently stained 
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with DyLight™ 488 streptavidin. All studies were performed in triplicate with at least n 
= 50,000 events per sample.  
Inhibition studies: SB-505124 and JNJ-10198409 (Sigma, USA) were used to inhibit 
TGF-β1 and PDGF signaling, respectively. These chemicals bind to their corresponding 
cell surface receptors and block signaling pathways. Concentrations were determined 
from literature review and titration studies, which were used to identify maximum 
concentration associated with non-significant viable cell loss. These initial concentration 
ranges have previously been used to inhibit TGF-β1 dependent migration [17] and 
differentiation [18] of MSCs and PDGFR-β dependent kinase activity in NIH 3T3 [19] 
and proliferation in tumor cells [19, 20]. For all studies, MSCs were treated with 1uM 
SB-505124 and/or 50 nM JNJ-10198409 for one hour prior to soluble factor treatment. 
Reverse transcription polymerase chain reaction (RT-PCR): RNA was isolated from 
treated cells using RiboZol RNA extraction reaction, and cDNA was synthesized by 
reverse transcription using the i-Script cDNA synthesis kit (BioRad). Primers were 
designed using NCBI primer-blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/). All primer sequences are listed in 
Appendix A (Table A-1). Polymerase chain reactions (PCR) were carried out to amplify 
gene sequences as per manufacturer’s recommendation for Promega PCR reaction kit. 
Gel electrophoresis was performed with 2% (w/v) agarose gel to visualize amplified 
DNA. All values are normalized to endogenous control 18sRNA.  
Statistics: Each experiment was performed with 3 or more replicates, and all values 
expressed as the mean ± s.e.m. One way Anova test with repeated measures was used to 
determine statistical significance of experiments involving four groups. For comparison 
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between groups, Tukey’s HSD post-test was used. Significance was reported as * (for 
p<0.05), ** (for p<0.005) and *** (for p<0.0005).    
4.3.  RESULTS 
MSCs respond mechanically to TGF-β1 and PDGF treatment: MPTM was used to 
characterize the mechanical response of MSCs to soluble factors. For these studies, the 
intracellular rheology was characterized from the MSDs of 100 nm probe particles 
embedded in the cytoplasm (Figure 4-1). In control MSCs, particle MSDs varied linearly 
with time (Figure 4-1A), demonstrating the viscous nature of the MSC cytoplasm [1], 
which corresponded with viscous moduli (G”) that were higher than the elastic moduli 
(G’) for all frequencies (Figure 4-1B). After treatment with PDGF (5ng/mL), the majority 
of particle MSDs still varied linearly with time, indicating that the cytosol remained 
primarily viscous. Furthermore, the average viscous and elastic moduli of PDGF-treated 
cells were similar to control, although a small population of particles (approximately 5%) 
encountered a more elastic cytoplasm. Treatment with an equivalent amount of TGF-β1 
resulted in a homogeneous particle transport response, with 100% of the embedded 
particles encountering a more elastic cytoplasm as evident by particle MSDs independent 
of time and corresponding elastic moduli higher than the viscous moduli for all 
frequencies.  This homogeneous stiffening response was also seen in cells treated with 
PDGF and TGF-β1; however, combination treatment resulted in 6-fold lower MSDs 
compared to TGF-β1 at τ = 1s (p<0.05). At the corresponding frequency, the average 
elastic moduli of MSCs treated for 24 hours with TGF-β1 and the combination of PDGF 
and TGF-β1 was 9-fold and 100-fold greater than control (p<0.05), respectively. Further 




Figure 4-1. TGF-β1 alters rheology of MSC cytosol. (A) The ensemble averaged mean 
squared displacements (MSD) of 100 nm particles embedded in the cytoplasm of  
murine Balb/C MSCs incubated for 24 hours in control media (CM), 5ng/ml platelet 
derived growth factor (PDGF), 5ng/ml transforming growth factor- β1 (TGF-β1) and 
combination of PDGF and TGF-β1- each 5ng/ml (PDGF+TGF-β1). (B) The time-
dependent ensemble averaged MSDs of 100 nm particles embedded in the cytoplasm of 
MSCs were converted to frequency-dependent elastic (G′) and visous (G″) moduli using 
a custom written algorithm for MATLAB software. 
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treated cells remain primarily viscous as δ remains greater than 45 degrees; whereas for 
TGF-β1 treated cells individually and in combination with PDGF the phase angle was 










Figure 4-2. Phase angle (δ in degrees) proportional to the ratio of viscous to elastic 
modulus was calculated using G’ and G”. Phase angle of control and PDGF treated cells 
are greater than 45
0
 (degrees) indicating viscous cytosol whereas for TGF-β1 treated cells 
individually and in combination with PDGF display phase angle well below 45
0
, 
indicating severe cytosolic stiffening. 
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Effect of soluble factor treatment on MSC morphology: Since previous work has 
shown that MSC shape can contribute to cell stiffness [21], we stained the cells after 
twenty four hours with crystal violet to analyze cell morphology.  In good agreement 
with the previous work, dramatic cell elongation was associated with TGF-β1 treatment, 
both individually and in combination with PDGF (Figure 4-3A). The morphological 
change was more quantitatively assessed using a cell shape factor (CSF) which varies 
from 0 for a line to 1 for a perfect circle. The CSF decreased significantly (p<0.0005)  in 
response to TGF-β1 treatment alone and in combination with PDGF indicating that cells 
had elongated in response to these treatments (Figure 4-3B). Interestingly, PDGF alone 
did not alter cell morphology; however, it significantly (p<0.0005) enhanced the 
elongation effects of TGF-β1. 
TGF-β1 alters cytoskeletal organization of MSCs: Next, changes in cytoskeletal 
organization were examined with immunofluorescence staining of microtubules (green), 
filamentous actin (red), and nuclei (blue) (Figure 4-4A). Confocal images revealed 
condensed and elongated microtubules and actin filaments in cells treated with TGF-β1 
alone or in combination with PDGF. Cells treated with TGF-β1 alone were also arranged 
in a parallel structure, which was somewhat disrupted in combination treatment. For 
combination treatment condition, the nuclear shape factor (NSF), which is the nuclear 
equivalent of CSF, was reduced significantly (p<0.0005), indicating that nuclei had 
elongated (Figure 4-5A) which may be required for navigating narrow pores within the 
ECM [1]. The actin stress fiber density, which measures the density of bundled actin 
filaments relative to cell area, was significantly ( p<0.05) higher in MSCs treated with 









Figure 4-3. MSCs elongate dramatically in response to TGF-β1. (A) Brightfield images 
of soluble factor-treated MSCs after 24 hours stained with crystal violet. MSCs elongated 
dramatically in response to TGF-β1 individually and in combination with PDGF; 
whereas, MSCs did not respond to PDGF treatment alone (scale bar: 100µm). (B) Cell 
shape factor (CSF) was determined by analysis of bright field images with image J.  CSF 
was used to characterize the elongation of the cell, with a shape factor of 1 indicating a 









Figure 4-4. MSCs reorganize their cytoskeleton in response to TGF-β1 after 24 hours. 
(A) Confocal images of soluble factor-treated MSCs stained with Phalloidin (F-actin, 
red), anti-α-tubulin (microtubules, green), and DAPI (nucleus, blue). The shape and 
cytoskeletal organization of CM and PDGF-treated MSCs were similar; whereas, TGF-
β1 with or without PDGF treated MSCs were elongated with condensed cytoskeletal 








Figure 4-5. Cytoskeletal parameters (A) nuclear shape factors and (B) stress fiber 
density were determined by analysis of confocal images with custom MATLAB 
routine.  (A) The nuclear shape factors were used to characterize the elongation of the 
nucleus, with a shape factor of 1 indicating a perfect circle and 0 indicating a straight line 
respectively. (B)  The stress fiber density was used to characterize the density of actin 
stress fibers per cell area. Cytoskeletal changes observed in TGF-β1-treated (with or 
without PDGF) MSCs were confirmed using the cytoskeletal parameters, which indicated 
reductions in cell and nuclear shape factors and increase in stress fiber densities. Results 
are reported as average ± s.e.m. (n=3). 
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Both PDGF and TGF-β1 signaling are essential for cellular stiffening: TGF-β1 
profoundly influenced the morphology, cytoskeletal structure, mechanical stiffness of 
MSCs. Although the individual effects of PDGF on these aspects were not always 
identifiable, the addition of PDGF to TGF-β1 treatment amplified these cellular 
responses, indicating possible interaction between these two signaling pathways. To 
begin to understand this interaction, flow cytometry analysis was performed to analyze 
the surface expression of PDGFR-β in all four conditions (Figure 4-6A-C). Though the 
percentage of positive cells (PPC) was only decreased for conditions containing PDGF 
(Figure 4-6B), mean fluorescence intensity (MFI) was significantly (p<0.005) decreased 
for all three treatments indicating that TGF-β1 treatment also results in reduced binding 
sites for PDGF ligand (Figure 4-6C). Additional studies suggest that this decrease in MFI 
was not due to a decrease in PDGFR-β surface expression, but increased binding of 
PDGF to its receptor blocking the antibody binding. Incubation with PDGF at short time 
scales (~1hour) revealed a rapid decrease in PDGFR MFI before changes in receptor 
levels from altered gene expression would be able to occur, suggesting the decrease is 
due to increased levels of bound PDGF (Figure 4.7A-C). This result inferred that the cells 
treated with TGF-β1 alone were also experiencing increased levels of PDGF signaling 
through the activation of autocrine PDGF signaling loop.  
To better elucidate the roles of PDGF and TGF-β1 signaling on mechanical 
stiffening, we decoupled these interactions with small molecule inhibitors JNJ-10198409 
and SB-505124 in tandem with soluble factor treatment. SB-505124 binds to intracellular 
domain of TGF-βR type I (ALK4, ALK5 and ALK7) and stops phosphorylation of 
SMADs to inhibit downstream TGF-β1 signaling [22]. JNJ-10198409 is a selective 
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PDGFR-β kinase inhibitor, which blocks downstream PDGF signaling [23]. We chose 
the concentration of each inhibitor (JNJ-10198409-50nM; SB-505124-1µM) based on 24 
hour viability given a range of inhibitor concentrations. MSCs incubated for one hour 
with SB-505124 prior to treatment with TGF-β1 alone or in combination with PDGF 
maintained their viscous cytosolic property similar to that of control MSCs (Fig 4-8). 
More interestingly, JNJ-10198409 incubation completely prevented both TGF-β1 and 
combination of PDGF and TGF-β1 induced stiffening (Figure 4-8). These results suggest 




Figure 4-6. Role of PDGFR-β in TGF-β1 signaling. (A) Flow cytometric analysis of 
surface PDGFR-β expression on MSCs in response to soluble factor treatment at 24 
hours. (B-C) Percent positive population and mean fluorescence intensity of treated 
cells were calculated from FACS-DIVA. PDGF and combination of PDGF and TGF-
β1 resulted in reduced available surface receptors after 24 hours; TGF-β1 treatment 












Figure 4-7. TGF-β1 does not interact with PDGFR-β at short time scales (A) Histograms 
of soluble factor MSCs from flow cytometry for PDGFR-β (after 1 hour). Gated percent 
positive population of MSCs compared to the negative population (black histogram) is 
indicated as mean±s.e.m. (B) PPC and (C) MFI calculated for CD140b/PDGFR-β after 




Figure 4-8. PDGFR-β inhibitor reverses TGF-β1 mediated mechanical response. 
Effect of small molecule chemical inhibitors SB-505124 (blocks TGF-βRI mediated 
signaling) and JNJ-10198409 (inhibits PDGFR-β mediated signaling) on the 
viscoelastic properties of soluble factor-treated MSCs were evaluated after 24 hours. 
The average mean squared displacements of 100 nm particles embedded in the 
cytoplasm of cells and frequency-dependent elastic (G’) and viscous (G”) moduli of 
inhibitor treated MSCs were similar to the control cells. 
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TGF-β1 regulates cellular stiffness and morphology via close control of actin-
binding proteins: The structure and function of cytoskeletal actin is controlled by actin-
binding proteins (ABPs) [24,25], which bind to actin filaments and modulate their length, 
stability, and cytoskeletal attachments. With the high impact of TGF-β1 on cytoskeletal 
structure, its effects on subset of ABPs were assessed using RT-PCR analysis. We 
investigated the effects of soluble factor treatment on 5 different genes belonging to the 
ABP family. Tensin, a scaffolding protein that connects the actin cytoskeleton to the 
membrane via focal adhesion complexes has shown actin-bundling activity. Tensin-1 
(Tns1) was upregulated in a TGF-β1 dependent manner in MSCs (Figure 4-9, 4-10) and 
treatment with SB-505124 (TGF-βRI inhibitor) but not JNJ10198409 (PDGFR-β 
inhibitor) abrogated the positive response. We also found very similar response for 
troponin-t2 (Tnnt2) which interacts with stabilizing protein tropomyosin (stabilizes actin 
bundles by protecting them from ADF/cofilin) to regulate the interaction of actin and 
myosin. Bundling and crosslinking proteins regulate cell tension through close 
association with actin stress fibers and the gene for bundling protein α-actinin-1 (Actn1) 
was upregulated in TGF-β1 treated cells. Interestingly, the positive regulation of this 
actin crosslinking gene was dependent on both PDGF and TGF-β1 signaling pathway 
because both SB-505124 and JNJ-1019409 inhibited the gene upregulation. Finally, we 
examined the effect of soluble factor treatments on the expression of ezrin (Ezr) and 
moesin (Msn) that belongs to ERM family of membrane anchoring proteins which tether 
intracellular actin domains to cell membrane. Msn, which directly regulates cortical 
rigidity in dividing cells, was up-regulated in TGF-β1 treated cells; however, Ezr 
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expression was downregulated. These regulation patterns of ERM proteins are in 




Figure 4-9. TGF-β1 closely regulates ABPs. (A) PCR amplified gene expression of actin-
binding proteins were confirmed using 2% (w/v) agarose gel. Four lanes are 
corresponding to CM, PDGF, TGF-β1 and the combination of PDGF and TGF-β1 (from 
left to right). Tensin-1 (Tns-1), troponin t2 (Tnnt2), moesin (Msn), and α-actinin-1 
(Actn1) were all upregulated; whereas, ezrin (Ezr) was downregulated. 18s RNA was 




Figure 4-10. PDGF signaling influences TGF-β1 mediated mechanical stiffening. (A) 
SB-505124 blocked the upregulation of TGF-β1 mediated expression of actin-binding 
proteins tensin-1 (Tns-1), α-actinin-1 (Actn1), troponin T2 (Tnnt2) and moesin (Msn) 
compared to control after 24 hours. (B) JNJ-10198409 selectively blocked Actn1 and 
pdgfb gene activation in PDGF and TGF-β1 treated cells compared to control. Gene 
expression was normalized using 18sRNA as internal control. Results are reported as 
average ± s.e.m. (n=3). 
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4.4.  DISCUSSIONS 
MSCs are highly proliferative adult stem cells that are involved in wound healing and 
tissue regeneration [27]. They have been shown to change their mechanical properties 
both during differentiation [9] as well as recruitment to sites of inflammation such as 
wound sites and tumor tissue [27]. Though soluble factors are critical for both of these  
processes [28,29], little is known about the effects of individual growth factors on the 
intracellular mechanical properties of MSCs. In this study, we investigated changes in 
mechanical properties, including intracellular rheology, cytoskeletal organization, as well 
as molecular pathways differentially regulated by 24-hour treatment with PDGF and/or 
TGF-β1.  
The cytoskeleton that underlies cell rheological properties is a network of highly 
heterogeneous and dynamic filamentous proteins that not only provide the cell with 
structural support but also actively rearrange to permit motility. Alterations in 
morphology and cytoskeletal have been correlated with changes in the intracellular 
mechanical properties [1]. Particle-tracking methods probe the local viscoelastic nature of 
the cell, which is determined from the transport rates of particles embedded in 
cytoplasm.  Particle tracking has been used in vitro to characterize the mechanical 
properties of networks of reconstituted cytoskeletal proteins [30,31] and in vivo to probe 
the dynamic mechanical properties of filamentous proteins in the cell cytoskeleton [32]. 
Kole et al. previously found that Swiss 3T3 fibroblasts migrating at the edge of a scratch 
wound assay undergo heterogeneous stiffening response, characterized by increased 
rigidity of cortical actin, to PDGF treatment [3].  
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Multiple particle tracking microrheology was used in this study to determine the 
effects of TGF-β1 and PDGF on the microscopic mechanical properties of MSCs (Figure 
4-1). MSCs underwent a homogenous stiffening response to TGF-β1 treatment with the 
cytoplasm transforming into an elastic solid. The average MSD was used to determine the 
elastic moduli at ω=1 s
-1
and treatment with TGF-β1 resulted in 9-fold increased rigidity 
(Figure 4-1, Table 4-1). This homogeneous stiffening response was also seen in PDGF 
and TGF-β1 treated cells; however, the elasticity of the cytoplasm was increased further 
10-fold (p<0.05) with the addition of PDGF.  These marked shifts in viscoelastic 
properties of cells may be due to enhanced crosslinking among actin filaments, as similar 
mechanical strengthening of in vitro actin solutions is demonstrated from the formation 
of both orthogonal networks and ordered bundles, mediated by F-actin cross-
linking/bundling proteins. In vitro, α-actinin increased actin solution elasticity by 15-fold, 
at a molar ratio of 1:50 (0.03 µM α-actinin in 15µM actin) [33]. Further studies with 
other cross-linking (Filamin) and bundling proteins (Fascin) individually or in 
combination with α-actinin increased the formation of entangled and crosslinked 
structures of bundled fibers, resulting in stiffer actin gel mechanics [31,34]. The 
difference in elasticity of combination of PDGF and TGF-β1 treated cells compared to 
TGF-β1 alone may be due to a more balanced role between cross-linkers and bundlers 
which gives rise to superior ordered architecture with higher stiffness. This surprising 
result highlights the importance of studying the effects of soluble factors on the 
mechanical properties of MSCs. Differences in the viscoelastic behavior of cells have 
been associated with differentiation potential [35], malignant transformation, and disease 
[36]. For instance, activation of latent TGF-β1 in soft tissues such as the kidney has been 
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deemed critical for tissue fibrosis [37] which may be due to stiffening of both cells and 
their remodeled environments.   
We further investigated more macroscopic cytoskeletal changes in response to 
TGF-β1 and PDGF by evaluating the cell shape factor and actin stress fiber density. 
Treatment with TGF-β1, but not PDGF, resulted in increased stress fiber density and cell 
elongation. Surprisingly, the effect of TGF-β1 was enhanced by the addition of PDGF, 
indicating that crosstalk in signaling pathways, is important in mediating this response 
(Figure 4-4, 4-5). Interestingly, TGF-β1 treated cells were aligned in parallel but 
introduction of PDGF with TGF-β1 increased the randomness in their orientation. The 
parallel alignment of TGF-β1 treated cells may be associated with increased production 
of fibrillar collagen [38,39]. Mannose-6-phosphate [40] and other TGF-β inhibitors 
[41,42] are used to prevent hypertrophic scars, which are often associated with increased 
collage I expression and parallel alignment of ECM proteins.  
TGF-β1 is also known for its role in directing MSC differentiation into bone, 
cartilage, and muscle [43] and for regulating the expression of other growth factors, 
including PDGF [44], important in stem cell growth, maintenance, and differentiation 
[45]. Although PDGF and TGF-β1 affect many cellular processes over longer time 
periods, the molecular and mechanical response to these factors was measured after a 24-
hour exposure, which minimized the effects of these processes on cellular mechanics. 
Over the 24-hour time period used in our studies, PDGF and TGF-β1 did not affect MSC 
differentiation, as determined by histological screening.  
Previous studies have explored molecular mechanism behind TGF-β1 dependent 
cytoskeletal remodeling and found important roles of small Rho-GTPases (RhoA, 
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CDC42, and Rac1) [46-48]. To correlate with cytoskeletal re-organization and 
mechanical stiffening response to TGF-β1 treatment, we examined the role of multiple 
genes belonging to the family of actin-binding proteins that directly control actin 
remodeling [24,25]. The actin-binding protein α-actinin acts as a crosslinker and bundler 
in reconstituted actin solutions [49] and organizes F-actin filaments in orthogonal or 
parallel structures in cells, contributing to both stress fiber formation and cellular 
stiffness [34]. Other proteins like fascin and transgelin interact more selectively with F-
actin, which is important for generating more structured actin networks like parallel 
bundles found in filopodia and stress fiber formation [50-52]. Increasing the thickness of 
these parallel bundles or reducing the degrees of freedom for polymeric actin movement 
through orthogonal crosslinking may contribute to high cell stiffness. 
Due to the complexities of intracellular control of actin mechanics originating from 
protein interactions and post-translation modifications, it is difficult to isolate the 
mechanical response to a particular protein or protein complex. Instead we focused on the 
roles of the principal signaling pathways affected by TGF-β1 and PDGF. The initial 
studies suggested PDGF can augment the effects of TGF-β1. Multiple studies have 
provided evidence of cross-talk between these two pathways [53,54]. We used small 
molecule receptor inhibitors to explore the role of PDGF and TGF- β1 signaling in the 
mechanical response (Figure 4-8). SB-505124 binds to TGF-βRI and inhibits 
phosphorylation of Smad2/3 to block TGF-β signaling. It has been shown to successfully 
block recruitment of MSCs to arteries [55] and block ALK5 mediated chondrogenesis of 
MSCs [18]. JNJ-10198409 is PDGFR-β tyrosine kinase inhibitor and it has been 
primarily examined to inhibit proliferation of different cell types [20,56]. Both inhibitors 
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have been tested independently to curb tumor growth, albeit through different 
mechanisms [20,57]. SB-505124 expectedly inhibited elongation and stiffening response; 
however, more interestingly, PDGFR-β inhibitor–JNJ-10198409 blocked these responses 
as well for both TGF-β1 alone and in combination with PDGF. We further investigated 
role of these inhibitors on relevant gene activation of ABPs such as tensin-1 (Tns1), α-
actinin-1(Actn1), troponin t2 (Tnnt2), moesin (Msn), using PCR and gel electrophoresis. 
After initial screening, we focused on 4 genes for each inhibitor based on differential 
response.  SB-505124 completely blocked the TGF-β1 mediated upregulation of all four 
genes (Figure 4-9A). Since PDGF individually does not regulate ABPs, we used JNJ-
10198409 to examine the role of PDGF signaling in combined soluble factor treated cells. 
Expectedly, JNJ-10198409 abrogated Pdgfb gene activation (Figure 4-9B). More 
interestingly, it selectively only blocked Actn1 activation. Combined with the previous 
results of complete inhibition of TGF-β1 mediated cell stiffening with JNJ-10198409, 
this data suggests that Actn1 is one of the key regulators of cell stiffening. However, a 
more detailed screening of ABPs with JNJ-10198409 is required to explore all the key 
elements of stiffening response. These studies provided evidence of integral role of 
PDGFR-β mediated signaling for individual TGF-β1 treatment. Furthermore, two 
different time scales, including short (~1 hour) (Figure 4-7) and long (~24 hours) (Figure 
4-6), were used to determine possible interaction between TGF-β1 treatment and 
PDGFR-β expression. At short time scale, available surface PDGFR-β expression was 
down-regulated for PDGF treated cells individually and in combination with TGF-β1 
compared to control (both by PPC and MFI, (Figure 4-7)). Similar trends were found to 
be true at longer time scale for PDGF and combination of PDGF and TGF-β1 (Figure 4-
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6A-C).  For TGF-β1 treated cells, surface expression of PDGFR-β was comparable to 
that of control cells at shorter time scale. However, surface expression of PDGFR-β on 
TGF-β1 treated cells were significantly (p<0.005) lower compared to control cells after 
24 hours (Figure 4-6B). Analysis of microarray data exhibit 0.5-fold (p<0.05) increase in 
PDGFB expression for TGF-β1 treated cells compared to control. This result was also 
confirmed using PCR. 
Data presented here strongly indicate cross-talk between PDGF and TGF-β1 
signaling pathways in regulating certain aspects of the mechanical and chemical response 
of MSCs. Up-regulation of Pdgfb and Pdgfrb in TGF-β1 treated cells might be due to the 
autocrine induction of PDGF signaling (Figure 4-11). Other studies have suggested 
establishment of the autocrine PDGF-loop in TGF-β1 treated cells albeit in different cell 
types [58,59]. This study suggests that this PDGF loop may be integral for TGF-β1 
mediated mechanical response. And for combination treatment, addition of recombinant 
PDGF protein amplifies the response from PDGF loop which later interacts with 
intracellular TGF-β1 signaling to modulate the rheological and cytoskeletal response.  
4.5.  CONCLUSIONS  
Soluble factors like PDGF and TGF-β1 are essential for normal tissue remodeling and 
wound healing and play an important role in the development of malignant diseases. The 
mechanical response of cells to these soluble factors in the niches remains poorly 
understood. This study indicates at the cellular level, TGF-β1 can induce cytoskeletal 
remodeling to change cell rheology and shape to modify cell behavior. Additionally, we 
found that PDGF signaling is integral for TGF-β1 mediated mechanical response of cells. 
The TGF-β1 signaling pathway is manipulated in numerous therapeutic applications from 
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regenerative medicine to cancer. This study shows that PDGF may be a viable target in 
manipulating certain aspects of this signaling pathway.   
Previous studies have correlated PDGF and TGF-β1 induced cytoskeletal 
remodeling and mechanical response of cells to small Rho GTPases [46-48] that control 
actin organization via intermediate actin binding proteins. However, the genetic 
manipulation of Rho GTPases to specifically control cell shape and mechanics can be 
complicated since they directly participate in multiple signaling pathways. Here we 
demonstrated that PDGF and TGF-β1 signaling uniquely regulate key ABPs to induce 
mechanical changes. Such a finding can lead to more specific control of mechanical 









Figure 4-11. Schematic presentation of TGF-β1 mediated stiffening response. A 
simplified diagram correlating mechanical response of MSCs to the treatment with TGF-
β1 by molecular regulation of actin-binding proteins such as stabilization and 
crosslinking factors. After 24 hour exposure to TGF-β1, alterations in morphology and 
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CHAPTER 5: EFFECT OF TGF-β1 AND PDGF-BB ON 





Cell adhesion and migration are critical processes that play key roles in normal and 
pathological tissue development. Several studies have investigated the role of specific in 
vivo factors in regulating adhesion and migration of multiple cell types including 
mesenchymal stem cells (MSCs). The primary objective of this study is to develop MSCs 
that can adhere and migrate in the wound bed. Therefore, we examined the effect of two 
wound healing site specific factors, TGF-β1 and PDGF, on MSC migration and adhesion. 
Combining these results with the mechanical characterization from previous studies 
(chapter 4) can provide new insights into MSC behavior in vivo. 
5.1.  INTRODUCTION 
The adhesion of cells to the extracellular matrix (ECM) or cell surface receptors 
(like VCAM-1) is essential for cell survival and viability [1].  Anchorage dependent cells 
bind to the ECM via surface adhesion molecules such as integrins, cadherins, and 
selectins to avoid programmed cell death by anoikis [2,3]. Integrins initiates the adhesion 
process and essentially perform as both linkers and sensors for cells by bridging the bond 
between the cell cytoskeleton and the ECM [2]. Activated integrins are heterodimeric 
transmembrane glycoprotein receptors that consist of α and β subunits [4].  There are 24 
non-covalent dimers that have been identified to form from the family of 18 ‘α’ and 8 ‘β’ 
subunits (total 26) in mammalian cells. Among these combined 26 individual subunits, 
  
 95 
αv (CD51) and β1 (CD29) participate in forming the majority of the heterodimeric 
clusters in MSCs [4]. The cytoplasmic domain of the bound and activated integrins 
recruits a host of intracellular cytoplasmic molecules to form focal adhesion complexes 
[2], which contain mechanical (talin, vinculin, filamin, α-actinin) and chemical signal 
transducers (FAK, paxilin, src family kinases) [5-7]. After cells are anchored to surfaces, 
bound integrins provide bidirectional relay of both biophysical and biochemical signals 
for cells carry out a plethora of activity in the tissue regeneration site including migration 
[6,8].  
Cell migration is important for both normal tissue regeneration and growth of 
pathological processes like cancer. During growth and regeneration, migration process 
allows cells to distribute and replace damaged cells, actively participate in tissue 
remodeling and angiogenesis [9-11]. Adhesive strength does not directly correlate with 
cell migration; however, it is critical and controls certain aspects of cell motility [12,13]. 
The migration process begins with the protrusion of lamellipodia and the formation of 
new focal adhesions at the leading edge of the cell [12,14]. The cytoskeleton undergoes 
rapid reorganization during this event. Polymerized actin binds to the focal adhesion 
complex and the contractile force created by myosin motors acts via polymerized actin to 
pull up the trailing edge of the cell and push it in the forward direction [12,13]. During 
migration, cells dynamically establish and break bonds on the migrating surface [15]. 
Migrating cells require an intermediate level of adhesive forces, since highly adhesive 
cells would have difficulty breaking these bonds during migration and non-adhesive cells 
could not generate the traction forces required for engaging the ECM [16,17].  
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Chemical and physical stimuli have been shown to alter cell shape and cytoskeletal 
organization and influence cell migration by activating cytoskeletal mediators [18-22]. 
PDGF has been universally reported to be a very potent chemoattractant [23] and plays 
key role to recruit smooth muscle cells and MSC-like pericytes for angiogenesis in vivo 
[24,25]. In case of TGF-β1, migration results remain intriguingly cell specific. For 
example, TGF-β1 can induce epithelial to mesenchymal transition (EMT) of epithelial 
cells that contributes to invasiveness of cells with increased motility both in vitro and in 
vivo [26-28]. In contradiction, TGF-β1 has been shown to inhibit migration of endothelial 
cells [29,30]. In fact, independent studies have reported contradictory effects of TGF-β1 
on MSCs, underlining the importance of more thorough characterization of such 
interaction. Here, we found that TGF-β1 treatment resulted in increased expression of 
integrins and enhanced adhesion of MSCs with different ECM proteins. We also 
examined the effects of the soluble factors on regulating cell motility to close an 
artificially created scratch. Although, PDGF controlled motility of MSCs predominantly, 
TGF-β1 enhanced the PDGF-mediated migration effect in a directional motility assay 
mimicking a scratch wound. Since the effects of the soluble factors on these functions 
can vary from cell type to cell type significantly, it is necessary to investigate the 
functional outcome of MSCs under the influence of the soluble factors both individually 
and in combination. 
5.2.  MATERIALS AND METHODS 
Materials: IMDM, DMEM, L-glutamine, penicillin-streptomycin and trypsin were 
purchased from Mediatech and fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals. Recombinant human proteins TGF-β1 and PDGF-BB (referred to as PDGF) 
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and antibodies for flow Cytometry were purchased from Biolegend. Rhodamine-
Phalloidin, were purchased from Invitrogen. All other reagents were purchased from 
VWR unless otherwise specified. 
MSC isolation and culture: Murine MSCs were isolated from the bone marrow of 6-10 
weeks old adult male Balb/C mice (Charles River Laboratories, Wilmington, MA) and 
cultured in normal growth media (IMDM media supplemented with 20% FBS, 2 mM L-
glutamine, 100U/ml penicillin, and 100U/ml streptomycin). Purified MSCs between 
passages 2-6 were used for all studies.  
Centrifugal force based adhesion assay: This fluorometric assay was used to evaluate 
the effect of soluble factor treatment on MSC adhesion to native ECM, collagen (COL), 
or fibronectin (FBN). Briefly, MSCs were trypsinized and seeded in a 96 well plate that 
was coated with 10 µg/ml desired ECM molecule or left uncoated for native ECM control 
(n = 8 wells per condition). After 24 hours treatment with soluble factors, cells were 
labeled with a transmembrane fluorescent viability marker, Calcein AM (Anaspec), and 
an initial fluorescence reading was recorded. Cells were detached by centrifuging 
inverted plates at 500 x g for 5 minutes before recording a final fluorescence reading. The 
adherent fraction was determined by normalizing the final florescence values with the 
initial pre-spin values. 
Flow cytometry: MSCs were analyzed with a BD LSR-II flow cytometer to capture the 
effects of soluble factor treatment on the cell surface adhesion markers. Briefly, both 
treated and untreated cells were detached from 10 cm dishes, centrifuged, and suspended 
in 100 µl cold FACS buffer (2% FBS, 1mM EDTA in PBS). Cells were then incubated 
with one of the following anti-mouse antibodies (dilutions in parentheses): PE-CD51 
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(1:20), FITC-CD29 (1:100), AF-647-MVCAM1/CD106 (1:200); APC- MVCAM1/ 
CD106 (1:200). All studies were performed in triplicate with at least n = 50,000 events 
per sample. 
Immunofluorescence staining:  To visualize focal adhesion protein vinculin, MSCs 
were cultured and treated on glass cover-slips in 24-well plates. Cells were then fixed 
with 4% formaldehyde before permeabilization with Triton X-100 and blocking with 
horse serum. Cells were stained for one hour at room temperature with 1 µg/mL rabbit 
anti-vinculin, followed by combination of 1:1000 goat anti-rabbit Alexa Flour 488 
(secondary for vinculin Ab) and 1:200 Rhodamine Phalloidin. Coverslips were then 
washed three times before sealing with Vectashield (Vector Labs) containing DAPI. All 
cells were visualized using Zeiss LSM 510 UV/NLO confocal microscope. All image 
analysis was performed in custom-written MATLAB algorithms. 
Motility and scratch assay: MSCs were cultured at a sub-confluent density for motility 
assay. For the scratch assay, cells were cultured as a confluent monolayer on uncoated 
24-well plate and a gap was created by removing cells with a pipette tip. Wells were then 
washed to remove detached cells before staining with NucBlue Live Cell dye (Invitrogen, 
Carlsbad, CA) or Hoechst for 30 minutes. Cells were then treated with soluble factors 
before placing them on Nikon Eclipse Ti inverted epifluorescent microscope, which was 
maintained at 37°C and 5% carbon dioxide throughout the experiment using an In vivo 
Scientific environmental cell chamber. Both brightfield (BF) and DAPI images were 
taken at multiple points at 10 minutes interval for 6-8 hours at 10x magnification. The 
locations of cell nuclei, segmented from fluorescent images, were tracked in MATLAB to 
define cell traces. The cell migration coefficients and directional velocities were 
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determined by fitting the traces to the persistent random walk model [31]. Briefly, mean 
square displacements were calculated      𝑑  𝜏)) from the two dimensional tracking 
data and was used for fitting the following equation: 
⟨𝑑  𝜏)⟩  4𝜇{𝑡 − 𝑃[1 − 𝑒    ]} 
P= persistence time and 𝜇=migration coefficient. 
Statistics: Each experiment was performed with 3 or more replicates, and all values 
expressed as the mean ± s.e.m. One way Anova test with repeated measures was used to 
determine statistical significance of experiments involving four groups. For comparison 
between groups, Tukey’s HSD post-test was used. Significance was reported as * (for 
p<0.05), ** (for p<0.005) and *** (for p<0.0005).    
5.3.  RESULTS  
TGF-β1 and PDGF alter adhesive strength of MSCs: A functional adhesion analysis 
with a centrifugation force based adhesion assay (Figure 5-1) revealed MSCs treated with 
PDGF were significantly ( p<0.05) less adhesive than control cells on tissue culture 
plastic (32.9%); whereas, TGF-β1 treated cells were up to 54% more adhesive than 
control (p<0.0005). Combination treatment with PDGF and TGF-β1 also resulted in 
increased MSC adhesion (p<0.0005) relative to control (75%), indicating that cell 
adhesion is largely regulated by TGF-β1. After 24 hours, the adhesion of MSCs with 
COL and FBN was similar to tissue culture plastic (TCP), since MSCs likely had 
sufficient time to secrete their own ECM proteins. 
TGF-β1 and PDGF alter expression and distribution of cell adhesion molecules: We 
next sought to analyze the changes in the expression of the focal adhesion complexes that 
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link the actin cytoskeleton to the extracellular environment and adjacent cells by staining 










Figure 5-1. TGF-β1 enhanced adhesive strength of MSC on substrate. Centrifuge-based 
adhesion assay was used to determine the effects of soluble factor treatment on the 
adhesion of MSCs on tissue culture plastic (TCP) coated with collagen -10ug/ml (COL) 













Figure 5-2. Vinculin expression remain unchanged after soluble factor treatment. (A) 
Confocal images of soluble factor-treated MSCs stained with Phalloidin (F-actin, red), 
anti-vinculin (green), and DAPI (nucleus, blue) (scale bar: 20µm). (B) Normalized focal 






expression (quantified using confocal micrographs in MATLAB) did not change 
significantly (Figure 5-2B), the pattern of expression was more distributed throughout the 
population of cells and localized to tips on an individual cell level when exposed to TGF-
β1.   
To reconcile these differences, flow cytometry was used to analyze differences in 
expression of integrin subunits β1 (CD29, Figure 5-3A) and αv (CD51, Figure 5-3A), 
which bind directly to the extracellular matrix, and cell adhesion molecules vascular cell 
adhesion molecule-1 (VCAM-1) (Figure 5-4A), which mediate cell-cell adhesion (also 
ICAM-1 Figure 5-4A) with endothelial cells and leukocytes. PDGF treatment had very 
little effect on the expression of these integrin molecules, with only significant 
differences in mean fluorescence intensity (MFI, Figure 5-3B) for αv (reduced 
expression) but not β1 integrin. In contrast, treatment with TGF-β1 significantly altered 
both integrin expressions as demonstrated by increased MFI for CD29 (p<0.005) and 
CD51 (p<0.0005). However, both TGF-β1 and PDGF treated cells demonstrated similar 
trend for the examined cell-cell adhesion molecules and significantly reduced percentage 
of positive cells (PPC) for VCAM-1 and ICAM-1 (Figure 5-4B). The altered integrin 
expression for TGF-β1 treated cells may explain the observed differences in adhesion and 
further demonstrates the important role of TGF-β1 in cell adhesion. 
PDGF controls cell motility in vitro: A random motility assay was used to evaluate the 
effect of soluble factors on cell motility. For these studies, MSCs were seeded on 
uncoated 24 wells plate and grown to subconfluency prior to treatment. In presence of 
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soluble factors, the directed motility and migration coefficients were determined by 
tracking the cell nuclei with NucBlue live cell dye. PDGF enhanced random migration 




Figure 5-3. TGF-β1 increased cell surface integrin expression. (A) Histograms from 
flow cytometric analysis of surface cell adhesion molecules using fluorescent labeled 
antibodies for αv (PE) and β1 (FITC) integrins on MSCs after 24 hours treatment with 
soluble factors. Gated percent positive population of MSCs compared to the negative 
population (black histogram) are indicated as mean±s.e.m. on top right of overlayed 
histograms (red for CM, green for PDGF, blue for TGF-β1 and violet for PDGF+TGF-
β1).  Histograms from flow cytometry were analyzed using FACS-DIVA for mean 
fluorescence intensity (MFI). Surface integrin expressions of PDGF-treated cells were 
unaffected; whereas TGF-β1 individually and in combination increased both integrin 










Figure 5-4. PDGF and TGF-β1 downregulated surface cell-cell interaction (A) 
Histograms from flow cytometric analysis of surface cell-cell adhesion molecules using 
fluorescent labeled antibodies for VCAM-1 (APC) and ICAM-1 (APC) on MSCs after 24 
hours treatment with soluble factors. Gated percent positive population of MSCs 
compared to the negative population (black histogram) are indicated as mean±s.e.m. on 
top right of overlayed histograms (red for CM, green for PDGF, blue for TGF-β1 and 
violet for PDGF+TGF-β1).  (B) Histograms from flow cytometry were analyzed using 
FACS-DIVA for percent positive population (PPC). Surface VCAM-1 and ICAM-1 
expressions of PDGF-treated cells were decreased; whereas TGF-β1 individually and in 
combination reduced both CAM expression significantly compared to the control.  




both individually and in combination with TGF-β1, however; no significant difference 
was observed between individual PDGF treatment and combination. Both migration 
coefficient and mean directional velocity were increased significantly for PDGF treated 
cells compared to control (Figure 5-5). TGF-β1 failed to generate any motility response 
from the cells both individually and in combination. Similar PDGF dominant migration 
activities were observed for an in vitro scratch assay (that mimics the wound site) as cells 
migrated toward an artificially created gap to establish new cell-cell contact. PDGF alone 
and in combination drove MSCs towards the scratch bed to close the gap more 
efficiently. Though TGF-β1 alone did not induce a directional motility response, the 
effects of PDGF were enhanced when TGF-β1 was added (Figure 5.6.). 
5.4.  DISCUSSION 
MSC adhesion to ECM can modulate cell spreading, mechanotransduction and migration 
[32]. Tissue specific soluble factors interact with MSCs to mediate their engraftment and 
migration [33]. Here we investigated effect of two such soluble factors PDGF and TGF-
β1 on MSC adhesion and migration in vitro.  
TGF-β1 treatment induced significant increase in cell adhesion (p<0.0005 for 
plastic), whereas, addition of PDGF did not enhance the effects of TGF-β1, indicating 
that crosstalk between these signaling pathways (Figure 4-11) is likely not important in 
regulating adhesion to ECM. Previous studies have suggested that increase in integrin 
binding to ECM and clustering can lead to adhesion strengthening. Since αv (CD51) and 
β1 (CD29) participate in forming most integrin heterodimers, we examined effect of the 
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soluble factor treatments on their surface expression. Both integrin expressions were 





Figure 5-5. PDGF control random cell motility (chemokinesis) on 2D plastic surface. (A, 
B) Cell motility was evaluated in soluble factor treated MSCs by (A) random cell 








Figure 5-6. TGF-β1 enhanced PDGF mediated cell migration towards “wound” gap 
on 2D plastic surface. (A, B) Cell motility was evaluated in presence of soluble factors 
after creating scratch on a confluent monolayer of MSCs by (A) cell migration 





expressions for the same TGF-β1 dependent conditions suggest that increased integrin 
expression does not lead to integrin-CAM mediated cell-cell adhesion. We also 
investigated the effect of soluble factors on focal adhesion (FA) complex protein 
vinculin. Adhesion and migration processes are shown to be dependent on FA-related 
parameters including, spatio-temporal distribution and size of FAs [7,15,20]. 
Interestingly, overall expression of vinculin (the load bearing member of FA complex) 
did not change; however, vinculin was more distributed.  A possible explanation can be 
that with the enhanced number of stress fibers and increased intracellular stiffness, the 
force distribution can be optimized by distributing sites of interaction between FA and 
actin-fibers. Additionally, more surface integrins can form clusters at these new sites of 
interactions leading to adhesive strengthening with enhanced number of cell-ECM bonds.  
MSC migration is critical for in vivo events such as cancer growth and wound 
healing [34,35]. We investigated role of PDGF and TGF-β1 in regulating MSC migration 
in both random (motility assay) and directed manner (scratch assay). and PDGF was 
found to enhance the MSC motility in both assays in agreement with literature [23]. 
PDGF receptor mediated activation of PI3-K (Phosphoinositide-3-kinase)-AKT pathway 
is central for cell migration [36,37] and it is possibly contributing to the enhanced 
migration observed in our studies. However, the role of TGF-β1 is not as straightforward 
as PDGF and we found both in literature and our studies that it can be much more 
complex. TGF-β1 individually did not have any effect on migration of MSCs. 
Interestingly, TGF-β1 enhanced PDGF dependent MSC migration in a scratch assay. For 
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individual TGF-β1 treatment, adhesive strengthening can be detrimental to migration 
albeit generating higher intracellular contractile forces. And it is only in presence of 
PDGF; TGF-β1 treated cells can generate enough contractility elongation to overcome 
the adhesive force barrier to induce migration. However, due to formation of high density 
of actin stress fibers in this case, cells prefer more persistent migration in one direction 
leading to enhanced motility in scratch assay. Taken together, these results suggest that 
TGF-β1 plays a profound role in controlling the individual cell and overall tissue 
mechanical behavior in tumors and wound sites.  
5.5.  CONCLUSIONS 
Both PDGF and TGF-β1 have been shown interact with MSCs in vivo regenerative 
niches and their influence on MSC function can be complementary. TGF-β1 has been 
shown to induce differentiation of MSCs into contractile smooth muscle cells (SMCs); 
whereas, endothelial cell-secreted PDGF is important in recruitment SMCs and 
stabilization of the newly formed blood vessels. We found that TGF-β1 increased 
integrin-dependent adhesion strength and enhanced directional migration of cells in the 
presence of other chemotactic factors such as PDGF. The enhanced integrin based 
adhesion can increase engraftment efficiency and the increased directional migration can 
be beneficial for homing towards inflamed tissues. Combined with the previously 
observed morphological elongation and mechanical stiffening of MSCs (chapter 4) after 
TGF-β1 treatment, these results provide new insights into MSC function in presence of 
these soluble factors at regeneration sites. More importantly, this study can be used to 
design preconditioning of MSCs prior to transplantation (both locally and systemically) 
to increase efficacy of cell based therapeutics.  
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CHAPTER 6: MOLECULAR PROFILING OF MESENCHYMAL 




Though a variety of soluble factors have been shown to increase MSC migration and 
engraftment [1,2], the complex signaling cascades controlling this response remain 
poorly understood. Our earlier work showed that both murine [3] and human [4] MSCs 
undergo dramatic cytoskeletal stiffening in response to the cocktail of pro-migratory 
molecules released by tumor cells. These soluble factors include PDGF and TGF-β1, 
which play important roles in recruiting MSCs to target sites and influencing their growth 
and regenerative capacity [5]. To gain molecular insight into the role of these two factors 
in regulating MSC behavior, we characterized their effects individually and in 
combination on the transcriptional profile of MSCs using high-throughput genome wide 
microarray analysis.  
6.1.  INTRODUCTION 
Mesenchymal stem cells (MSCs) migrate from their in vivo niche and engraft in the 
damaged tissues and tumors where they aid in tissue regeneration and growth by 
secreting soluble growth factors, interacting with immune cells, and differentiating into 
tissue-specific cell types [6-9]. Soluble growth factors secreted by inflamed tissues and 
tumors interact with MSCs in their in vivo niche and control their mobilization and 
recruitment to the target sites [7]. When the cells are infused systemically or directly 
transplanted locally for therapeutic applications, the initial interaction with these niche 
specific factors (especially after reaching the target site) can largely determine the fate of 
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incorporated MSCs and is not completely understood. Here we have investigated the role 
of two representative factors present in inflammatory niches, including PDGF-BB 
(referred as PDGF) and TGF-β1, on MSC gene expression. 
 Platelets at the site of inflammation release PDGF and TGF-β1 to orchestrate 
recruited cell functions that benefit regeneration process [9,10]. In chronic illness, the 
rapid degradation of these growth factors has been associated with impaired cellular 
function in wound bed [11,12]. In previous chapters, treatment of MSCs with TGF-β1 
resulted in pronounced elongation, cytoskeletal reorganization, increased stress fiber 
density, enhanced adhesion and increased stiffness; whereas, PDGF profoundly increased 
cell motility but did not modify other physical aspects of the cells. To explore the broader 
molecular impact of these growth factors on MSCs, we conducted a detailed gene 
expression analysis (Affymetrix) of MSCs grown in media supplemented with PDGF and 
TGF-β1 alone and in combination. Molecularly high-throughput gene expression analysis 
(Affymetrix MG430 2.0) demonstrated significant gene expression changes when MSCs 
were treated either with TGF-β1 alone or in combination with PDGF; however, PDGF 
alone resulted in relatively few changes in comparison to TGF-β1. Pair-wise comparisons 
of the genome-wide expression profiles of treated and control cells revealed TGF-β1 
regulated genes involved in cytoskeletal organization, cell adhesion and extracellular 
matrix (ECM) remodeling, production of actin-binding proteins, and epithelial-to-
mesenchymal transition (EMT).  
6.2.  MATERIALS AND METHODS 
Materials: IMDM, DMEM, L-glutamine, penicillin-streptomycin and trypsin were 
purchased from Mediatech and fetal bovine serum (FBS) was purchased from Atlanta 
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Biologicals. Recombinant human proteins TGF-β1 and PDGF-BB (referred to as PDGF) 
were purchased from Biolegend. All other reagents were purchased from VWR unless 
otherwise specified. 
MSC isolation and culture: Murine MSCs were isolated from the bone marrow of 6-10 
weeks old adult male Balb/C mice (Charles River Laboratories, Wilmington, MA) and 
cultured in normal growth media (IMDM media supplemented with 20% FBS, 2 mM L-
glutamine, 100U/ml penicillin, and 100U/ml streptomycin). Briefly, tibiae and femurs of 
the mice were extracted and crushed in FBS. Cold PBS and collagenase I (2mg/ml) 
solutions were added subsequently to facilitate cell extraction from bone with minimal 
cell damage. Finally, the solution mixture was filtered (70 µm cell strainer) and 
centrifuged (1000xg for 10 minutes) to recover the bone marrow cell population in pellet 
form. Media was supplanted regularly to remove non-adherent BM cell populations. 
Once the adherent cells reached 80-90% confluency, the cell culture was expanded and 
subsequently purified using EasySep™ Mouse SCA1 Positive Selection Kit (StemCell 
Technologies). Purified MSCs between passages 2-6 were used for all studies.  
Soluble factor treatment: Soluble factor dilutions were created in serum-free DMEM 
immediately before use. All experiments were carried out with four conditions: serum-
free control media, 5ng/ml PDGF, 5ng/ml TGF-β1 and combination of PDGF and TGF-
β1- each 5ng/ml.  MSCs were treated for 24 hours unless otherwise specified.   
Microarray data analysis: Gene expression analysis of treated and untreated MSCs was 
performed in triplicate using three independent replicates per condition. The Affymetrix 
GeneChip Mouse Genome 430 2.0 microarray chips were used for these studies. 
Affymetrix .CEL files were processed using Expression Console Software Version 1.1 
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with the RMA algorithm (Robust Microarray Analysis). The normalized expression 
values of each gene were log2 transformed and used for further analysis.  
Unsupervised analysis: From the initial 45,101 probe sets (genes) on the Affymetrix 
Mouse Genome 430 2.0 chip, 42,129 displayed marginal differences in expression across 
all samples (standard deviation ≤ 0.5 from the mean of all samples) and were filtered out. 
The remaining 2,972 probe sets were employed in the unsupervised clustering analysis 
using the Spotfire Decision Site 9.1.2 (TIBCO Software: http://spotfire.tibco.com/) with 
the UPGMA (unweighted average) method and the Euclidean distance as the similarity 
measure.   
Supervised analysis: From the initial 45,101 probe sets (genes) on the Affymetrix Mouse 
Genome 430 2.0 chip, 13,777, 19,672 and 19,618 genes displayed expression values ≥ 
0.2 SD from the mean across the control and the cell treatments of PDGF, TGF- β1 and 
PDGF-TGF-β1 respectively. From these, the differentially expressed genes between each 
cell treatment (PDGF, TGF-β1 and PDGF-TGF-β1) and the control samples were 
computed using stringent false discovery rate (FDR) criteria. The significant probe sets 
were 842 (FDR of 1.5%), 10,617 (FDR of 2.4%) and 8,117 (FDR of 2.13%) for the 
PDGF, TGF-β1 and PDGF-TGF-β1 respectively. These genes were employed in pathway 
enrichment analyses using the GeneGO software. 
6.3.  RESULTS  
Expression profiling reveals distinct genes and pathways in MSC treated with the 
TGF-β1, PDGF and the combined PDGF and TGF-β1: From the initial 45,101 probe 
sets of the Affymetrix Mouse Genome 430 2.0 chip, any housekeeping genes and 
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potential experimental noise was excluded by discarding all probe sets with expression 
variation of standard deviation ≤ 0.5 among the 12 samples of cell treatments and 
controls. The remaining 2,972 probe sets were used for the unsupervised hierarchical 
clustering and initial expression pattern discovery (Figure 6-1). Unsupervised analysis 
showed expression profiles of TGF-β1 grouped with the combined PDGF and TGF-β1 
cell treatment and did not group with the PDGF and control treatments. 
In order to investigate further the differences between each cell treatment and 
control, and between treatments, we estimated the number of significantly differentially 
expressed probe sets. The Significance Analysis of Microarrays (SAM) revealed greater 
number of differentially expressed probe sets for TGF-β1 (10,617 probe sets of FDR 
2.4% or 23.5% of the initial 45,101 probe sets of the Affymetrix Mouse Genome 430 2.0 
chip) but fewer probe sets for the combined TGF-β1 and PDGF (8,117 differentially 
expressed probe sets of FDR 2.13% or 18.0% of the initial 45,101 genes of Affymetrix 
Mouse Genome 430 2.0 chip). Even fewer probe sets were estimated for PDGF (only 842 
differentially expressed probe sets of FDR 1.5% or 1.87% of the initial 45,101 genes of 
Affymetrix Mouse Genome 430 2.0 chip). 
The number of significantly differentially expressed genes between treatments 
and controls were 589, 6,751, and 5,292 for the PDGF, TGF-β1 and the combined PDGF 
and TGF-β1 treatments respectively (Figure 6-2). We identified the most highly regulated 
(both up and down) genes for each treatment condition sorting by the log2ratio value. The 
top 15 upregulated genes and downregulated genes for each treatment conditions 










Figure 6-1. Heatmap of Unsupervised clustering of all microarray probes. Heatmap 
indicating significant changes (FDR p value ≤ 0.05) in gene expression (black, no 
change; red, increase; green, decrease) due to serum-free, PDGF, TGF-β1 and 







Adiponectin (Adipoq), endothelial cell-specific molecule 1 (Esm1), insulin-like growth 
factor 2 (Igf2) and vascular cell adhesion molecule 1 (Vcam1) genes were all 
downregulated for all three conditions; however, no such commonality was observed for 
upregulated genes. Additionally the genes regulated for the combination treatment were 
heavily populated by the genes controlled by TGF-β1 treatment, suggesting that TGF-β1 
plays the dominant role in the combination treatment. It is also noteworthy that for both 
TGF-β1 and combination treatment, the most upregulated genes were associated with 
adhesion and extracellular matrix (ECM) remodeling (example: Periostin (Postn), 
tenascin C (Tnc), hyaluronan synthase 2 (Has2)).     
Figure 6-2. Venn diagram depicts the number of genes regulated in a soluble factor 
treatment-specific and non-specific manner within each segment (n=3). 
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Differentially expressed genes display distinct pathway enrichment in TGF-β1 and 
PDGF: The most significantly enriched pathways for each treatment regime are listed in 
Table 6-1. Consistent with the highly upregulated gene list, the most significantly 
enriched pathway across all treatments was the Cell Adhesion and ECM remodeling 
pathway. Other significantly enriched pathways among TGF-β1 treated cells were 
cytoskeletal remodeling and developmental processes related to epithelial-to-
mesenchymal transition (EMT). The pathways significantly enriched after the combined 
PDGF and TGF-β1 treatments were a mixture of pathways significantly enriched in one 
or other of the individual treatments. The role of TGF-β1 became more prominent when 
we clustered the total number of regulated genes for a particular pathway (Figure 6-3). 
TGF-β1 alone and in combination regulated most genes for motility, adhesion, EMT, 
cytokines, chemokines, and chemokine receptors. Since TGF-β1 has most profoundly 
influenced the transcriptional profile of MSCs, we analyzed the three significantly 
regulated networks to provide further insight (Figure 6-4, Figure 6-5 and Figure 6-6). 
Networks depicting cytoskeletal remodeling and adhesion pathways share a number of 
molecules due to the interconnectivity between the processes. Genes encoding actin 
binding proteins (α-actinin, arp2/3), focal adhesion proteins (talin, vinculin) and wnt 
signaling pathway molecules that actively participate in actin reorganization were all 
upregulated. Similar constitutive upregulation was also noticeable for the cell surface 
integrins that connect the cytoskeletal network to ECM. Although the small RhoGTPases 
were not differentially regulated at the mRNA level, other elements of the actin-myosin 
contractility pathway were differentially regulated in  
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Table 6-1. Treatment specific 10 most significant enriched pathways. 
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Figure 6-3. (A) Total number of differentially expressed genes of specific pathways (B) 













Figure 6-4. Regulated genes related to cytoskeletal remodeling in TGF-β1 treated cells 
compared to control. Red thermometer: genes transcriptionally up-regulated in MSCs; 














Figure 6-5. Regulated genes related to Chemokines and Adhesion in TGF-β1 treated 
cells compared to control. Red thermometer: genes transcriptionally up-regulated in 















Figure 6-6. Regulated genes related to Epithelial to mesenchymal transition (EMT) in 
TGF- β1 treated cells compared to control. Red thermometer: genes transcriptionally up-
regulated in MSCs; blue thermometer: genes transcriptionally down-regulated in MSCs 
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TGF-β1 treated cells, including nucleotide exchange factors that regulate RhoGTPases 
like EIF, myosin light chain phosphatase (MLCP) and LIM kinase-2 (LIMK2). During 
EMT, transcription factors like TCF, LEF (associates with β catenin in Wnt signaling 
pathway), snail mediate cytoskeletal remodeling that contribute to invasive phenotype of 
the cells. These transcription factors along with expression of N-cadherin (mesenchymal 
marker) are used a biomarker for EMT process. All these factors were found to be 
upregulated in TGF-β1 treated MSCs.  
TGF-β1 closely control of actin-binding proteins: The structure and function of 
cytoskeletal actin is controlled by actin-binding proteins (ABPs), which bind to actin 
filaments and modulate their length, stability, and cytoskeletal attachments [13,14], . 
With the high impact of TGF-β1 on cytoskeletal structure, its effects on ABPs were 
assessed using microarray analysis from curated GO gene sets available from Broad 
Institute’s Molecular Signature Database (MSigDB) (Table 6-2). Stabilizing proteins 
were constitutively up-regulated in TGF-β1 treated MSCs; whereas, capping and severing 
proteins were constitutively down-regulated (Table 6-2). Tropomyosin stabilizes actin 
bundles by protecting them from ADF/cofilin and interacts with troponin to regulate the 
interaction of actin and myosin. Tropomyosin-1 (Tpm1) along with troponin (Tnnt2) was 
up-regulated; whereas, its inhibitor tropomodulin (Tmod3) was down-regulated in TGF-
β1 treated cells. Bundling and crosslinking proteins regulate cell tension through close 
association with actin stress fibers. Bundling proteins α-actinin-1 (Actn1) and transgelin 
(Tagln) were up-regulated and other cross-linkers such as α2 and β2 spectrins (Spna2, 
Spnb2) which play a key role in membrane anchoring of actin, were down-regulated. 
Membrane anchoring proteins, which tether intracellular domains of actin to membrane  
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proteins, were mostly up-regulated with the exception of ezrin (Ezr) and aforementioned 
spectrins. Ezr belongs to ERM family of anchoring proteins with other members being 
moesin (Msn) and radixin (Rdx). Msn, which directly regulates cortical rigidity in 
dividing cells, was up-regulated in TGF-β1 treated cells; however, change in Rdx 
expression was not significant. These regulation patterns of ERM proteins are in 
agreement with previous studies with TGF-β1 treated epithelial cells. 
6.4.  DISCUSSION 
We have previously characterized the effects of soluble growth factors PDGF and TGF-
β1 both alone and in combination on the physical and functional properties of MSCs. 
While PDGF did not significantly influence the physical properties of MSCs, cells 
exhibited enhanced motility in its presence. On the other hand TGF-β1 enormously 
affected both physical and functional behavior of the cells as suggested by dramatic 
elongation, cytoskeletal reorganization, intracellular stiffening and adhesion 
strengthening on matrix. For the combined treatment, cellular properties were dictated 
predominantly by TGF-β1, however, synergistic effects were identified for certain 
aspects such as intracellular stiffening, elongation and directed migration towards scratch.  
To understand cytoskeletal re-organization and mechanical stiffening response, 
we focused on genes that encode for actin-binding proteins (ABPs) that directly control 
actin remodeling. The filamentous actin cytoskeletal network is dynamically regulated by 
several classes of ABPs: cross-linkers and bundlers, which construct higher order 















severing;  nucleation and branch forming proteins, which initiate filament formation; 
monomer binders, capping and severing proteins controls the polymerization and 
depolymerization of actin filaments. Cells treated with TGF-β1 and combination of 
PDGF and TGF-β1 up-regulated gene expression of bundling, crosslinking and 
stabilizing proteins. Other groups of proteins associated with branch formation, capping 
and severing were generally down-regulated, facilitating unidirectional growth of actin 
filaments and stress fibers. Crosslinking and bundling proteins can affect both the overall 
network architecture and the ability to dynamically re-organize these networks.  
 MSC treatment with TGF-β1 also resulted in enhanced expression of matrix 
proteins, like collagen (Col), fibronectin (Fbn), and tenascin C (Tnc), and matrix 
metalloproteinases (Mmp) (Table C-2) important in remodeling the ECM of the wound 
bed and tumor microenvironment. Intracellular mechanical forces on the local 
environment may induce further remodeling of the extracellular matrix through physical 
interactions. Taken together, these results suggest that TGF-β1 has a profound role in 
controlling the individual cell and overall tissue mechanical behavior in tumors and 
wound sites.     
6.5.  CONCLUSIONS  
In summary, genome wide microarray analysis demonstrated the effect of TGF-β1 on the 
transcriptional profile of MSCs, which was much more profound than PDGF; however, 
cross talk between the two signaling pathways can synergistically enrich and influence 
certain MSC behavior. Genes essential for cytoskeletal reorganization, adhesion and 
matrix remodeling were constitutively upregulated in a TGF-β1-dependent manner. 
Changes in gene expression after treatment with TGF-β1 were corroborated with the 
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functional differences observed in chapter 4-5, including (1) actin-binding protein 
mediated elongation and stiffening and (2) integrin mediated adhesive strengthening. 
Interestingly, genes related to multiple differentiation pathways were also regulated by 
TGF-β1, suggesting that short-term treatment with TGF-β1 simultaneously influences 
multiple lineage-specific differentiation pathways. Combined with high number of 
upregulated soluble factors, and ECM related genes, these results suggest that TGF-β1 
plays a very critical role in inflammatory niches to regulate MSC function and fate at 
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CHAPTER 7: TGF-β1 PRETREATMENT OF MESENCHYMAL 
STEM CELLS SUSTAINED IMPROVED FUNCTION BOTH IN 




Wound healing is a complex biological process where recruited cells play a central role in 
regeneration. In cases of both acute and chronic wounds, this cellular response is arrested, 
contributing to non-healing wounds. The ability of mesenchymal stem cells (MSCs) to 
self-renew and differentiate into multiple connective cell lineages has distinguished them 
as ideal candidates for wound healing. Previous studies have demonstrated that 
transplanted MSCs can revive the wound healing process with improved wound closure 
rate and neovascularization in diabetic mice. However, the interaction of MSCs with 
soluble factors already present in these regenerative niches is not well characterized. 
Increased understanding of these interactions can lead to avenues for more efficient 
design of MSC-based therapeutics. We have previously demonstrated that transforming 
growth factor (TGF-β1), highly expressed in inflammatory sites, can stimulate MSCs to 
dramatically alter their physical and mechanical properties. More importantly, genome 
wide microarray results suggest that treated cells exhibit upregulated genes for adhesion, 
migration, and differentiation. In this study, we show MSCs pre-treated with TGF-β1 for 
24 hours, show improved adhesion, and differentiation even after removal of stimulus 
leading to improved wound healing in mice. 
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7.1.  INTRODUCTION 
Injury to the skin results in the activation of the wound healing process, which is a 
complex series of events that includes inflammation, formation of granulation tissue, 
remodeling of an extracellular matrix (ECM), re-epithelialization, and scar tissue 
formation [1,2]. Growth factors are essential in mediating these wound healing stages, 
which proceed continuously from the time the skin is damaged until a scar is formed 
[3,4]. Elderly patients and patients suffering from chronic illness, including diabetes, 
ischemia, or hypertension, develop chronic wounds when the wound healing process is 
arrested in a state of chronic inflammation [1,5-8]. Two of the factors that have been 
associated with the formation of chronic wounds are: (1) impaired production of 
cytokines and growth factors and (2) reduced angiogensis (blood vessel formation) [9]. 
Mesenchymal stem cells (MSCs) (adult stem cells derived from bone marrow) have 
previously been shown to promote more rapid wound healing in diabetic mice, which was 
attributed to increased cytokine production [5]. Our study focused on the optimization of 
MSC migration in the wound bed. We hypothesized that migrating MSCs that 
disseminated throughout the wound bed would contribute to the formation of granulation 
tissue, which would constrict the wound for more rapid wound closure. Improved MSC 
migration could also improve the spatial and temporal activity of growth factors and 
cytokines since they were secreted from MSCs that disseminated throughout the wound 
tissue. More effective treatments for chronic wounds are urgently needed. Current 
therapies, which include wound debridement, negative-pressure therapy, growth factor 
replacement, biological dressing, skin grafts and cell-based therapies, have only increased 
the healing rate by up to 50%, and often times, this result was only temporary.  
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This study sought to understand if TGF-β1 pretreatment induced a sustained 
modification in MSC phenotype and behavior. TGF-β1 treatment resulted in dramatically 
elongated morphology and this phenotype was maintained even after 24 hours of removal 
of the stimulus. Similarly, TGF-β1 pretreated cells sustained the enhanced surface 
expression of αv, β1 and β3 integrins as determined by flow cytometry and subsequent 
higher adhesion to both glass and substrate compared to control cells. Pretreated MSCs 
demonstrated enhanced differentiation potential along multiple lineages including, 
osteogenic, adipogenic and myogenic phenotypes. Injection of TGF-β1 pretreated MSCs 
at the periphery of skin wounds resulted in increased wound closure rates compared to 
control MSCs. TGF-β1 pretreated MSCs also demonstrated greater distribution and 
migration towards the center of the wound compared to control cells. The persistent 
characteristics of TGF-β1 pretreated cells can be beneficial for treatment of chronic 
wounds, where cell functions are arrested due to rapid degradation of soluble factors. 
7.2.  MATERIALS AND METHODS 
Materials: IMDM, DMEM, L-glutamine, penicillin-streptomycin and trypsin were 
purchased from Mediatech and fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals. Recombinant human TGF-β1 protein and flow cytometry antibodies were 
purchased from Biolegend. All other reagents were purchased from VWR unless 
otherwise specified. 
MSC isolation and culture: Murine MSCs were isolated from the bone marrow of 6-10 
weeks old adult male Balb/C mice (Charles River Laboratories, Wilmington, MA) and 
cultured in normal growth media (IMDM media supplemented with 20% FBS, 2 mM L-
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glutamine, 100U/ml penicillin, and 100U/ml streptomycin). Purified MSCs between 
passages 2-6 were used for all studies.  
Soluble factor pretreatment: Soluble factor dilutions were created in serum-free 
DMEM or IMDM immediately before use. Initially, MSCs were pretreated with serum-
free control media (CM), and 5 ng/ml TGF-β1 (diluted in serum free media) for 24 hours. 
Afterwards, the stimulations were removed and both control and pretreated cells were 
moved to serum free or specific differentiation induction media to determine the effects 
of pretreatment on MSC functions. To avoid confusion with the previous results, the 
removal of growth factor stimulus was assigned as t0; whereas the time points for each 
experiment was indicated as t0+t hours. For example centrifugation based adhesion assays 
described in this section were carried out at t0+24 hours.  
Fabrication of Polyacrylamide Substrates: Substrates were synthesized based on the 
protocol described before [10]. Briefly, glass coverslips were activated using 3-
aminopropyltrimethoxysilane and a mixture of the acrylamide and bis-acrylamide 
solution (10% acrylamide to 0.3% bis) was polymerized on the activated glass coverslips 
(Young’ modulus (E) ~ 34kPa). Substrates were coated with type I collagen solution 
(0.2 mg/ml) before cell culture. 
Adhesion Assay:  Control and pretreated MSCs were trypsinized and labeled with a 
transmembrane fluorescent viability marker, Calcein AM (Anaspec), in HBSS with 
divalents. Then the cells were allowed to adhere for three hours after stimulus was 
removed (t0+3h) in HBSS before taking an initial florescence reading. A final reading 
was taken after removing non-adherent cells by washing with HBSS to determine the 
adherent fraction.  
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Centrifugal force based adhesion assay: This fluorometric assay was used to evaluate 
the effect of soluble factor pretreatment on MSC adhesion to native ECM. Briefly, 
control and pretreated MSCs were trypsinized and labeled with Calcein AM. Then the 
cells were seeded in an uncoated 96 well plate in serum-free media. At 24 hours after 
stimulus was removed (t0+24h), an initial fluorescence reading was recorded. Cells were 
detached by centrifuging inverted plates at 500 x g for 3 minutes before recording a final 
fluorescence reading. The adherent fraction was determined by normalizing the final 
florescence values with the initial pre-spin values. 
Morphological analysis: Control and pretreated MSCs were cultured for 24 hours after 
the removal of stimulus (t0+24h) and were stained with crystal violet. Cells were then 
imaged with stereoscope microscope and Motic camera. Cell borders were traced 
manually and cell shape factors, defined as 4*π*Area/ (Perimeter)
 2
, were determined 
using Image J.  
Microarray data analysis for differentiation related genes: Gene expression results 
from previously reported microarray analysis (chapter 6) was used for differentiation 
related gene analysis (CM vs TGF-β1)(t0). Lists of genes related to specific 
differentiation pathways were obtained from NCBI Biosystems and KEGG pathway 
databases. 
Differentiation studies: The effects of pretreatment on MSC differentiation were 
investigated for the following cell lineages: smooth muscle cells, adipocytes, and 
osteoblasts. Briefly, cells were cultured and pretreated on 24-well plates (CM vs TGF-β1) 
before switching to differentiation induction media. The induction media formulation and 
the staining method for each differentiation studies are described below. 
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Smooth muscle cell differentiation: For myogenic induction, IMDM was supplemented 
with 10% (v/v) FBS and 50 µM trans-retinoic acid for culturing the cells for 7 days 
(t0+7d).  The medium was changed every day. Cells were stained with Cy3 conjugated 
alpha-smooth muscle actin antibody (dilution 1:200). All cells were visualized using 
either an inverted Nikon Eclipse Ti or Zeiss LSM 510 UV confocal microscope. 
Adipogenesis: Adipogenic induction media was formulated using IMDM media 
supplemented with 10% FBS, 10% HS, 1% L-glutamine, 1% Pen-Strep, 5µg/ml Insulin, 
1.0 µM Dexamethasone, 0.5 µM Isobutylmethylxanthine, and  50 µM Indomethacin. 
Cells were cultured for 3 weeks after stimulus was removed (t0+21d) with induction 
media and negative control media before they were stained with Oil-Red O to visualize 
lipid rich vacuoles inside the cells. Cells were fixed in 4% formaldehyde for an hour 
before  being stained with freshly made Oil-Red O solution (3 parts of 0.5% (w/v) Oil-
Red O stock solution in isopropyl alcohol mixed with 2 parts of PBSD (PBS with 1% 
dextrin)).  
Osteogenesis: Cells were cultured in IMDM media with 20% FBS, 1% L-glutamine, 1% 
Pen-Strep, 1 nM Dexamethasone, 20 mM B-glycerophosphate, 50 µM Ascorbate-2-
phosphate, and 50 ng/ml L-thyroxine sodium pentahydrate. Osteogenic differentiation 
was analyzed after 3 weeks (t0+21d) using von-Kossa staining. Cells were fixed with 
neutral buffered 10% formalin solution for an hour and were subsequently exposed to 5% 
(w/v) silver nitrate solution in water under UV light. Osteogenic differentiation was 
evaluated by visualizing the silver deposition which replaced the calcium.  
Wound preparation and Mesenchymal stem cell transplantation: An in vivo punch 
biopsy wound healing model was used to determine the effects of MSC pretreatment on 
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wound healing. Briefly, hair was removed from the dorsal surface of anesthetized (100 
mg/kg ketamine and 10 mg/kg xylazine or isofluorane gas) 12-week old male Balb/C 
mice by shaving and Nair hair removal reagent. One 5 mm full-thickness skin wound was 
made on each side of the dorsal midline using a punch biopsy tool (to trace the wound 
perimeter) and iris scissors (to remove the tissue). Concurrently, pretreated MSCs were 
detached and labeled with the lipophilic tracer dye DiD (Invitrogen). Mouse 
mesenchymal stem cells (5.0x10
5
) suspended in a small volume of PBS solution (~100 
µl) were injected (30 gauge needle) intradermally at the periphery of wound tissue of 
anesthetized mice.  
Wound healing analysis: After seven days, animals were sacrificed and wound tissues 
were collected to image the fluorescently labeled MSCs. Wound tissues were stained 
with DAPI to highlight the nuclei and were then mounted on slide for imaging. The 
wound bed was imaged using Nikon Eclipse Ti inverted fluorescence microscope and an 
image of the entire wound area was created by stitching together all the individual images 
in Nikon Elements.  
Statistics: Each experiment was performed with 3 or more replicates, and all values 
expressed as the mean ± s.e.m. For comparison between two groups student t-test was 
used. One way Anova test with repeated measures was used to determine statistical 
significance of experiments involving more than two groups. For comparison between 
groups, Tukey’s HSD post-test was used. Significance was reported as * (for p<0.05), ** 
(for p<0.005) and *** (for p<0.0005).    
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7.3.  RESULTS  
TGF-β1 pretreatment enhances adhesive strength of MSCs: MSCs pretreated with 
TGF-β1 displayed higher adhesivity on both glass and polyacrylamide gel substrates 
(E~34kPa) after 3 hours (t0+3h) of removal of stimulus (Figure 7-1). In both cases, the 
adherent fraction of pretreated cells was normalized to the control cells. TGF-β1 
pretreated cells exhibited greater than 1.7 fold increase in adhesivity in both cases 
(p<0.05). A centrifugation force based adhesion assay was used to investigate the 
adhesive properties at longer time scales (~24 hours) (Figure 7-2). For this purpose, 
pretreated cells were seeded on uncoated tissue culture plastic (TCP) and were then 
subjected to centrifugation (500xg) at t0+24h. TGF-β1 pretreated cells maintained their 
higher adhesivity to ECM and exhibited a 4.2 fold increase in the adherent fraction 
compared to control.     
Effect of soluble factor pretreatment on distribution of cell adhesion molecules: We 
next sought to analyze the changes in the expression of cell surface adhesion molecules 
that control cell adhesivity to the extracellular environment and adjacent cells (Figure 7-
3). Integrin subunits αv (CD51), β1 (CD29), β3 (CD61), and vascular cell adhesion 
molecule-1 (VCAM-1) were analyzed using flow cytometry at 24 hours (t0+24h) after 
removal of stimulus. TGF-β1 pretreated cells significantly upregulated the expressions of 
the integrins while reducing VCAM-1 expression (Figure 7-3). Mean fluorescence 
intensity (MFI) of histograms further confirmed the trends of integrin upregulation and 
VCAM-1 downregulation due to TGF-β1 pretreatment (Figure 7-4). This result correlated 








Figure 7-1. Pretreated MSCs exhibit higher adhesive strength at both short (~3 hours) 
and longer time scales (~24 hours). (A) Pretreated MSCs (CM vs TGF-β1) plated on 
glass and polyacrylamide gels were washed after 3 hours to remove detached cells. (B)  
Centrifuge-based adhesion assay was used to determine the effect of soluble factor 






Figure 7-2. Analysis of cell surface adhesion molecules αv (CD51-PE), β1 (CD29-FITC) 
and β3 (CD61-PE), integrins and VCAM-1 (CD106 - FITC) using flow cytometry after 24 
hours of removal of stimulus. Black indicates negative cell population; whereas red and 
blue represent control and TGF-β1 pretreated cells respectively. TGF-β1 pretreated cells 
exhibit higher integrin expression and lower VCAM-1 expression at 24 hours after 




Figure 7-3. TGF-β1 pretreated MSCs maintain surface adhesion.characteristics. 
Histograms from flow cytometry were analyzed using FACS-DIVA for mean 
fluorescence intensity (MFI). Expressions of surface integrins αv (CD51), β1 (CD 29) 
and β3 (CD61) were increased significantly in TGF-β1 pretreated cells compared to the 
control; whereas TGF-β1 pretreatment reduced VCAM1 (CD106) expression 
significantly compared to the control.    Results are reported as average. (n=2). 
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Sustained morphological changes at 24 hours after TGF-β1 pre-treatment:  MSCs 
undergo dramatic elongation in response to TGF-β1 treatment. To examine the persistent 
effect of TGF-β1 on cell shape, pretreated MSCs were detached and reseeded on a new 
surface (TCP) with serum free media in the absence of stimulus for 24 hours (t0+24h). 
Cells were fixed and stained with crystal violet to analyze cell morphology using a cell 
shape factor (CSF) which varies from 0 for a line to 1 for a perfect circle. TGF-β1 
pretreated cells retained the elongation effect even after 24 hours (t0+24h) (Figure 7-5). 
The cell shape factor of TGF-β1 pretreated cells was significantly lower than its control 
counterpart indicating dramatic elongation (p<0.05).  
TGF-β1 pretreatment enhances the differentiation potential of MSCs: MSCs can 
differentiate into both mesodermal and non-mesodermal lineages and TGF-β1 is reported 
to have profound effects on MSC differentiation and cell fate. Here, the effects of short-
term exposure to soluble factors on the long-term differentiation potential of MSCs were 
characterized for multiple lineages. TGF-β1 pretreated MSCs along with the control cells 
were exposed to myogenic, adipogenic, and osteogenic differentiation media and were 
stained after 1 week (t0+7d) for myogenesis [11] and 3 weeks (t0+21d)  for adipogenesis 
and osteogenesis [12] (Figure 7-5). To determine smooth muscle cell differentiation, cells 
were immunostained with Cy3 conjugated alpha-smooth muscle actin (α-SMA). 
Pretreated MSCs exhibited higher expression of α-SMA compared to control indicating 
more mature smooth muscle cell (SMC) phenotype.  For adipogenesis, oil red o staining 
was used to visualize lipid vacuoles; whereas, von Kossa stained calcium nodules for 
osteogenesis. The percent of the total area that stained positive was quantified in all three 






Figure 7-4. Pretreated MSC maintain elongated phenotype (A) Brightfield images 
pretreated MSCs after 24 hours stained with crystal violet. TGF-β1 pretreated MSCs 
sustained elongated morphology in serum free media for 24 hours. (scale bar: µm). (B) 
Cell shape factor (CSF) was determined by analysis of bright field images with image 
J.  CSF was used to characterize the elongation of the cell, with a shape factor of 1 
indicating a perfect circle and 0 indicating a straight line. Results are reported as average 








Figure 7-5. Enhanced differentiation potential of TGF-β1 pretreated MSCs along 
multiple lineages. MSCs differentiated into adipocytes (column 1), osteoblasts (column 
2) and smooth muscle cells (column 3) in lineage-specific differentiation media as shown 
by staining. Adipocytes and osteoblasts were stained with oil red o and von Kossa 
respectively; whereas smooth muscle cells were stained with immunofluorescent dye Cy3 
conjugated α-Smooth Muscle Actin (shown in red).     
  
 148 
TGF-β1 pretreated cells demonstrated significantly higher coverage area for both 
osteogenesis and adipogenesis compared to control cells. For myogenic differentiation, 
normalized α-SMA expression was increased compared to control suggesting enhanced 
differentiation.   
TGF-β1 pretreatment enhances wound healing: Previous studies demonstrated that 
MSCs could be used to increase the rate of wound closure in full thickness skin wounds; 
however, untreated MSCs used in these studies resulted in a modest change in the rate of 
wound healing and long-term engraftment of MSCs was not clearly established [13]. We  
hypothesized that the sustained changes observed in TGF-β1pretreated MSCs would lead 
to more rapid wound closure and longterm engraftment in the tissue for improved healing 
of chronic wounds. A syngeneic mouse wound healing model was used to test this 
hypothesis with murine MSCs injected in immunocompetent mice. Each adult Balb/C 
mouse (n=3) used in this study was given two full thickness skin wounds, and 
fluorescently labeled MSCs (control and TGF-β1 pretreated) were injected at the 
periphery of each wound.  After 5 days, the area of the open wound was significantly 
lower for TGF-β1 preconditioned cells. After 7 days, skins were isolated from the 
sacrificed mice to image the entire wound area and to identify the distribution of 
fluorescently labeled MSCs in the wound bed (Figure 7-6A). TGF-β1 pretreated cells 
migrated more towards the center of the wound as image analysis in MATLAB revealed 
a 2.5 fold increase in directed migration for pretreated cells compared to control (Figure 













Figure 7-6. TGF-β1 pretreated MSCs close wound gap more rapidly. Open 











Figure 7-7. Pretreated MSCs exhibit enhanced migration in vivo. (A) Thresholded 
fluorescence images of skin tissue showed enhanced distribution of MScs towards center 
of the wound. (B) Quantification of directed migration towards the center of the wound. 
CM                         TGF-B1 
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7.4.  DISCUSSION 
Chronic wounds, which predominantly affect elderly and chronically ill patients, are a 
major health care burden. Although a plethora of wound healing treatments are clinically 
available, these are often unsuccessful in treating chronic wounds. Wound healing is a 
very complex process and understanding the coordinated action of the different types of 
cells and niche specific soluble and insoluble factors is of utmost importance for the 
development of modern wound care. Growth factors and bioactive materials have been 
used increasingly in recent times; however, on their own, there efficacy remains limited 
[14]. Recent studies have highlighted the benefits of using mesenchymal stem cells for 
wound healing that holds high hope for the future of the wound care [15,16]. However,  
characterization of MSCs with niche specific factors is still in its early stages. In this 
study, we have investigated interaction between mesenchymal stem cells and TGF-β1 a 
growth factor that plays an important role both in normal wound healing and in fibrosis. 
The current study was designed to determine if TGF-β1 induces a persistent alteration in 
MSC phenotype, leading to more efficient wound healing in vivo. 
Adhesion to substrates is essential for the survival of anchorage dependent cells 
like MSCs. We have initially characterized the adhesion profile of TGF-β1 pretreated 
cells at both short (~3 hours (t0+3h)) and longer time scales (~24 hour (t0+24h)). To 
determine the initial adhesion response at 3 hours, both glass and more compliable 
polyacrylamide (PA) gel substrates (E ~ 34kPa) were used. The stiffness of the substrate 
was chosen within the range of reported values for skin tissue [17]. A similar number of 
control and TGF-β1 pretreated MSCs were adherent to glass and PA gels before washing; 
however, fewer TGF-β1 pretreated cells were detached upon washing, indicating that 
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TGF-β1 pretreatment increased the adhesivity. This behavior of the pretreated cells can 
be traced back to the fact that surface integrin expression was increased in the presence of 
TGF-β1 and MSCs retained the surface phenotype even after removal of stimulus for 24 
hours (Figure 7-2, Figure B-1). Subsequently, we were interested in probing the effects of 
TGF-β1 pretreatment on the adhesivity of MSCs at longer time scales when the cells are 
no longer exposed to TGF-β1. A centrifuge-based adhesion assay was used to measure 
the adherent fraction on uncoated tissue culture plastic. These results would account for 
the adhesive strengthening due to changes in integrin expression and the secretion of 
native ECM proteins by MSCs. Previous studies have demonstrated enhanced ECM and 
other growth factor secretion from cells in response to TGF-β1 and transcriptional 
activation of the ECM genes were found to be upregulated previously (Figure 6-4, 
Appendix C). At 24 hours (t0+24h)  after removal of stimulus, pretreated MSCs displayed 
more than 4 fold increase in the adherent cell fraction compared to the 2 fold increase 
measured in our washing study after 3 hours (t0+3h) (Figure 7-1). Also, the surface 
expression of β1, β3 and αv integrins remained upregulated after 24 hours (t0+24h) with 
similar magnitudes in the mean fluorescence intensity as measured in Appendix B 
(Figure B-1). Additionally, pretreated cells maintained their elongated shape even after 
detachment and replating compared to the control cells.  
Due to their multilineage differentiation potential and capacity for in vitro 
expansion, MSC based therapeutics for wound healing hold distinct advantages over the 
currently used cell types such as fibroblasts and keratinocytes [15,18]. In addition, TGF-
β1 can further influence MSC differentiation along multiple lineages [19]. Previous 
studies have shown that short-term TGF-β1 exposure upregulated genes for specific 
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differentiation pathways; however, additional cues were required to induce mature 
phenotypes [20]. Analysis of our previous transcriptional results revealed a number of 
highly regulated genes that serve as early markers for lineage commitment; however, a 
distinctive pattern, indicating a specific type of differentiation could not be identified 
(Table 1). Thus, we hypothesized that short term TGF-β1 exposure could prime the cells 
to differentiate into multiple lineages in the presence of pathway specific supplements. 
To test this hypothesis, the effects of TGF-β1 pretreatment on differentiation along 
adipogenic, osteogenic and myogenic lineages were characterized. Pretreated MSCs 
exhibited enhanced and more mature phenotypes along all three lineages.  
Since, TGF-β1 pretreated cells exhibited enhanced adhesion and differentiation, 
we wanted to examine if the persistent altered phenotype can lead to increased wound 
healing in vivo. We found that TGF-β1 pretreated MSCs contributed to the closure of the 
wound and invaded the wound bed more efficiently (2.5 fold increase in directed 
migration towards the center of the wound). TGF-β1 pretreated MSCs maintained an 
increased surface β1 integrin expression which has been correlated with enhanced 
migration both in vivo and in vitro [21,22] and can be critical for the observed changes in 
migration. Additionally, pretreated MSCs displayed a more elongated phenotype,that had 
been associated with enhanced migration through smaller pores (Figure 3-10). Therefore, 
injected cells could invade wound tissue more efficiently leading to increased distribution 
. Previously, microarray data revealed upregulation of genes related to cytokines and 
ECM remodeling proteins (chapter 6, Appendix C) that can aid in the wound regeneration 
process. Other studies with pretreated MSCs have reported enhanced therapeutic efficacy 
in the inflammatory niche of myocardial infarction [23,24]. Taken together with the 
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presented results, pretreatment of MSCs can be critical for developing efficient cell-based 
therapeutics for inflammatory niches in vivo.  
7.5.  CONCLUSIONS  
The function of ex-vivo expanded MSC based therapeutics has been shown to be limited 
after reintroduction in vivo. To understand and improve MSC functions, we have 
previously characterized the mechanical and chemical response of MSCs to soluble 
factors in vitro. In brief, studies with soluble factor TGF-β1 provided enhanced 
mechanical response with cytoskeletal remodeling and stiffening (Chapter 4) that 
contributed to directional migration of MSCs. TGF-β1 treated cells also provided 
molecular response to indicate adhesive strengthening, ECM remodeling and 
differentiation (Chapter 5 and 6). This study illustrates that pretreatment of MSCs with 
TGF-β1 resulted in sustained improvement in migration, adhesion and differentiation 
even after removal of the stimulus in vitro. Subsequently, these pretreated cells enhanced 
the in vivo wound healing process, which may lead to improved therapeutic efficacy. 
Future studies with site specific factors will be used to guide new strategies for 
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8.1.  CONCLUSIONS 
Mesenchymal stem cells (MSCs) hold great promise as a source of donor cells for tissue 
engineering and regenerative medicine applications [1-3]. For this promise to be fully 
realized these cells must be expanded and manipulated ex vivo. However, fundamental 
changes in isolated MSCs during ex vivo expansion result in altered differentiation 
potential as well as loss of native homing ability [4-6]. We found that MSCs uniquely 
altered their mechanical phenotype to migrate more efficiently in response to tumor 
condition media compared to fibroblasts, suggesting that the rheological property can be 
used as a biomarker for more successful MSC homing to target tissues. However, tumor 
condition media cannot be used for mechanical characterization of MSCs for clinical 
purposes. We have identified that soluble factor transforming growth factor-β1 (TGF-β1) 
induced similar mechanical response from MSCs, and can be potentially used to 
characterize expanded ex vivo population. Interestingly, PDGF, a mitogenic growth 
factor, contributed significantly to stiffening response when combined with TGF-β1 and 
the inhibition of the PDGF signaling pathway led to complete reversal of the stiffening 
response (Table 8-1). Thus PDGF signaling pathway provides a viable target for 
disruption of abnormal TGF-β1 signaling mediated pathological conditions.     
MSCs displayed upregulated gene expression for both soluble and insoluble 
factors such as extracellular matrix molecules that can actively help in the tissue 
regeneration and remodeling process. Additionally, we have shown that TGF-β1 
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pretreated cells displayed enhanced differentiation and adhesion profile leading to 
increased in vivo wound healing. MSCs pretreated with TGF-β1 differentiated more 
efficiently to soft adipocytes, contractile smooth muscle phenotype and highly stiff 
osteoblasts, suggesting that pretreatment method can be universally adopted for a range 
of mechanically diverse tissue regeneration sites. Pretreated MSCs with enhanced 
differentiation potential can be beneficial for application in regenerative niches where 
multiple cell types are required for successful restoration of tissue functions (example: 
osteo-chondral cell lineages in arthritis).  
8.2.  RECOMMENDATIONS FOR FUTURE WORK 
This document outlines a detailed mechanical and molecular characterization of the 
interactions between MSCs and inflammatory site specific soluble factors that can be 
used to design new strategies for microenvironment specific MSC based therapy. Future 
efforts in the development of MSC based therapy will require further evaluation of MSC 
characteristics both in vitro and in vivo. Four potential areas of advancement are listed 
below: 
1. Effect of soluble factors on MSC mechanics and functions on substrates with 
different rigidities: In recent years biophysical cues such as matrix rigidity in concert 
with soluble factors has been shown to affect stem cell migration, proliferation and 
differentiation [7-10]. Future directions should include cells cultured on different 
matrix rigidities to further our understanding of MSC response to soluble factors.  
2. Genetic modification of ABPs to manipulate cell mechanics: Although, TGF-β1 
treated cells display dramatically different mechanical phenotype, it is also coupled 
with transcriptional changes in chemical and secretory properties of the cell. To study 
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the importance of cell mechanics in regulating key cell functions, it is essential to 
identify key signal transduction elements that can singularly modify mechanical 
properties of cells minimizing its effect on other aspects. MSCs can be genetically 
modified to express tailored proteins to enhance specific functions without inducing 
malignant transformation. For example, MSCs can be engineered to express α-actinin 
to manipulate its mechanical properties and characterize its effect on migration, 
adhesion and differentiation. The list of actin-binding proteins obtained from 
microarray analysis should be screened more rigorously to identify candidates similar 
to α-actinin.  
3. Effect of preconditioning on long term fate of MSCs: Mesenchymal stem cells 
contribute to wound healing via angiogenesis and differentiate into specific skin cell 
type [11]. MSCs secrete soluble factors to recruit host of other native cells and these 
paracrine effects of MSCs have been attributed to neovascularization in vivo [12]. 
Despite possessing the potential to form smooth muscle cells that stabilizes blood 
vessels [13, 14], MSCs have not been detected to actively participate in angiogenesis 
during wound healing.  In vitro co-culture of pretreated MSCs with endothelial cells 
can provide new insights to enhance the incorporation of stem cells in blood vessel 
formation. Additionally, long term fate of topically delivered MSCs in wound bed is 
not well established. The survival rate and phenotypical fate of injected MSCs 
(pretreated vs untreated) should be characterized in more detail.     
4. Characterizing global potential of pretreated MSCs in vivo: MSCs pretreated with 
TGF-β1 displayed enrichment in multiple functional networks that can be beneficial 
for different niches in vivo. Characterizing the functional behavior of pretreated 
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MSCs in these niches can provide new insights into the role of mechanical and 
chemical properties of MSCs in homing, engraftment, survival, migration and 
differentiation. Studies should be designed to address each aspect of the MSC 
function to improve the overall design. For example, pretreated MSCs should be 
infused in tumor carrying mice to evaluate homing and accumulation; whereas, to 
determine cell integration in mechanical environment, pretreated MSCs should be 


































Table 8-1: Summary of effect of soluble factor treatment with or without small molecule 













Control MSC 1.42 5.1 
MSC treated with TGF-β1 12.7 3.4 
MSC treated with PDGF 1.77 3.75 
MSC treated with PDGF and TGF-β1 142.64 3.75 
MSC treated with TGF-β1 and TGFβRI 
inhibitor 
2.20 6.00 
MSC treated with PDGF, TGF-β1 and 
TGFβRI inhibitor 
1.78 4.83 
MSC treated with TGF-β1 and PDGFR 
inhibitor 
1.33 3.50 
MSC treated with PDGF, TGF-β1 and PDGFR 
inhibitor 
1.20 5.19 
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Forward (5’-3’) CAA TCA ACG TCC GGG TGA C 104 
Reverse(5’-3’) GCC AAT CGT CTT TAC CAC CTG A 104 
Moesin 
(Msn) 
Forward(5’-3’) TCT TAT GCC GTC CAG TCT AAG T 121 




Forward(5’-3’) AGA AAT CCA GCT CCT AGC ACG 147 
Reverse(5’-3’) CTG TGA ACG TCT TCC TCT GCT 147 
Tensin-1 
(Tns1) 
Forward(5’-3’) TCA CAG CCT ACC AGT CTC TCT 166 
Reverse(5’-3’) ACA TCT GAG CCA CTT CAC GG 166 
PDGF-B 
(Pdgfb) 
Forward(5’-3’) TCC GTA GAT GAA GAT GGG GCT 163 





Forward(5’-3’) CCC GAT GGA GAG AGA GTG GA 155 
Reverse(5’-3’) CGA CGC TTT TCG ATC CTG TC 155 
18s rRNA 
Forward(5’-3’) CTT AGA GGG ACA AGT GGC G 107 
Reverse(5’-3’) ACG CTG AGC CAG TCA GTG TA 107 
Cdc42 
Forward (5’-3’) CCCATCGGAATATGTACCAACTG 78 
Reverse (5’-3’) CCAAGAGTGTATGGCTCTCCAC 78 
RhoA 
Forward (5’-3’) AGCTTGTGGTAAGACATGCTTG 138 
Reverse (5’-3’) GTGTCCCATAAAGCCAACTCTAC 138 
Rac1 
Forward (5’-3’) GAGACGGAGCTGTTGGTAAAA 138 
Reverse (5’-3’) ATAGGCCCAGATTCACTGGTT 138 
GAPDH 
Forward (5’-3’) AGGTCGGTGTGAACGGATTT 123 
























Figure B-1: Comparison of cell surface integrin expression between TGF-β1 treated 
MSCs at 24 hours and 48hours (additional 24 hours after  removal of TGF-β1). 
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APPENDIX C  
 
Table C-1: Regulation of critical genes related to defined functional groups. 
 




1422912_at Bmp4 1.22 -1.96 -3.17 
1415931_at Igf2 0.69 -2.8 -3.01 
1415854_at Kitl 0.6 -2.54 -3 
1450759_at Bmp6 0.02 -2.92 -2.94 
1438953_at Figf -0.18 -2.04 -1.86 
1422243_at Fgf7 -0.28 -1.93 -1.65 
1418471_at Pgf 0.02 -1.17 -1.19 
1419139_at Gdf5 -0.37 -1.51 -1.14 
1420653_at Tgfb1 0.14 1.21 1.06 
1419417_at Vegfc -0.26 1.06 1.29 
1426858_at Inhbb -0.52 0.79 1.31 
1449826_a_at Fgf2 -0.21 1.23 1.44 
1432032_a_at Artn 0.1 1.61 1.5 
1420909_at Vegfa -0.23 1.4 1.58 
1426238_at Bmp1 -0.1 1.58 1.7 
1419519_at Igf1 0.6 2.52 1.99 
1421207_at Lif -0.36 1.9 2.25 
1418711_at Pdgfa -0.33 2.28 2.6 
1423635_at Bmp2 -0.75 3.35 4.1 
Cytokines and Chemokines 
1419728_at Cxcl5 -0.09 -6.69 -6.6 
1423017_a_at Il1rn 0.16 -4.47 -4.63 
1422651_at Adipoq 0.23 -4.23 -4.45 
1419209_at Cxcl1 -0.32 -3.92 -3.61 
1422912_at Bmp4 1.22 -1.96 -3.17 
1417574_at Cxcl12 0.45 -2.65 -3.11 
1420380_at Ccl2 0.12 -2.95 -3.07 
1450759_at Bmp6 0.02 -2.92 -2.94 
1418126_at Ccl5 0.32 -2.51 -2.83 
1419083_at Tnfsf11 0.08 -2.21 -2.3 
1421228_at Ccl7 0.26 -1.48 -1.75 
1418219_at Il15 0.73 -0.96 -1.69 
1415803_at Cx3cl1 0.3 -1.1 -1.4 
1422080_at Il7 0.25 -1.22 -1.15 
1450297_at Il6 0.1 -0.97 -1.07 
1449982_at Il11 0.96 -1.11 2.08 
Extracellular matrix and adhesion 
1429072_at Col6a4 -0.57 -4.37 -4.42 
1415989_at Vcam1 -3.1 0.5 -3.32 
1450798_at Tnxb -0.27 -2.94 -3.28 
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Probe ID Gene PDGF vs Control TGF vs Control 
PDGF+TGF 
vs control 
Extracellular matrix and adhesion (continued) 
1449563_at Cntn1 -2.46 0.27 -2.56 
1420484_a_at Vtn 0.45 -2.67 -2.33 
1439713_at Itga1 -1.61 -1.62 -2.24 
1435386_at Vwf -0.01 -1.29 -1.79 
1420860_at Itga9 -1.86 -1.92 -1.48 
1427009_at Lama5 1.12 1.02 -1.45 
1450567_a_at Col2a1 -1.09 -1.09 -1.39 
1421997_s_at Itga3 -0.73 0.76 -1.27 
1426285_at Lama2 -0.38 -0.1 -1.1 
1447541_s_at Itgae 1.07 0.09 1.03 
1450501_at Itga2 0.35 0.54 1.06 
1417812_a_at Lamb3 -1.94 0.5 1.18 
1425815_a_at Hmmr -1.1 0.53 1.33 
1423760_at Cd44 1.36 0.15 1.37 
1420853_at Sdc3 0.38 1.09 1.37 
1416623_at Thbs3 1.18 -0.23 1.41 
1423110_at Col1a2 0.22 0.95 1.42 
1421006_at Col4a6 1.67 1.17 1.42 
1426918_at Itgb1 1.28 -0.07 1.48 
1427883_a_at Col3a1 1.37 -0.09 1.67 
1419703_at Col5a3 1.37 1.28 1.77 
1426642_at Fn1 1.25 -0.05 1.77 
1418599_at Col11a1 0.33 1.42 1.89 
1427512_a_at Lama3 0.61 1.05 2.02 
1416740_at Col5a1 2.22 0.16 2.07 
1419088_at Timp3 2.09 0.13 2.08 
1420450_at Mmp10 1.62 -0.49 2.11 
1416740_at Col5a1 0.27 2.31 2.14 
1424807_at Lama4 1.32 1.2 2.25 
1421511_at Itgb3 1.11 1.83 2.42 
1442140_at Tnn 1.13 2.76 3.48 
1416342_at Tnc 0.34 5.43 7.18 
Transcription factors and signaling molecules 
1423259_at Id4 -1.17 -3.4 -3.25 
1416630_at Id3 -0.11 -2.16 -2.45 
1422537_a_at Id2 -1.27 -1.43 -2.36 
1425895_a_at Id1 -0.75 -2.55 -2.14 
1450782_at Wnt4 -0.3 -1.37 -2.06 
1422771_at Smad6 -0.59 -1.31 -1.56 
1422019_at Tgfbr2 0.95 1.45 1.2 
1417621_at Nfatc1 0.9 2.33 2.6 
1425377_at Wnt1 0.25 2.05 3.05 
1421341_at Axin2 -0.13 4 4.21 
1425901_at Nfatc2 -0.83 3.76 4.32 
1420891_at Wnt7b -0.31 4.6 5.15 
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Table C-2: Top 15 up- and down-regulated genes in PDGF treated cells compared to 
control 
PDGF vs SF Gene Gene description 
Log2 
ratio 
1422651_at Adipoq adiponectin, C1Q and collagen domain containing -1.95 
1441313_x_at Lhx9 LIM homeobox protein 9 -1.76 
1449280_at Esm1 endothelial cell-specific molecule 1 -1.74 
1448162_at Vcam1 vascular cell adhesion molecule 1 -1.72 
1455251_at Itga1 integrin alpha 1 -1.57 
1421172_at Adam12 
a disintegrin and metallopeptidase domain 12 (meltrin 
alpha) 
-1.54 
1423555_a_at Ifi44 interferon-induced protein 44 -1.51 
1436739_at Agtr1a angiotensin II receptor, type 1a -1.43 
1448700_at G0s2 G0/G1 switch gene 2 -1.43 
1443170_at Cnnm1 cyclin M1 -1.39 
1418294_at Epb4.1l4b erythrocyte protein band 4.1-like 4b -1.38 
1455114_at Ccno cyclin O -1.30 
1448152_at Igf2 insulin-like growth factor 2 -1.19 
1419301_at Fzd4 frizzled homolog 4 (Drosophila) -1.14 
1450928_at Id4 inhibitor of DNA binding 4 -1.08 
1427747_a_at Lcn2 lipocalin 2 3.38 
1424733_at P2ry14 purinergic receptor P2Y, G-protein coupled, 14 3.18 
1454783_at Il13ra1 interleukin 13 receptor, alpha 1 3.03 
1417625_s_at Cxcr7 chemokine (C-X-C motif) receptor 7 2.83 
1418945_at Mmp3 matrix metallopeptidase 3 2.62 
1418133_at Bcl3 B-cell leukemia/lymphoma 3 2.50 
1417290_at Lrg1 leucine-rich alpha-2-glycoprotein 1 2.38 
1418021_at C4b complement component 4B (Childo blood group) 2.28 
1460469_at Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 2.19 
1449199_at Muc1 mucin 1, transmembrane 2.18 
1416576_at Socs3 suppressor of cytokine signaling 3 2.13 
1418675_at Osmr oncostatin M receptor 2.03 
1448326_a_at Crabp1 cellular retinoic acid binding protein I 1.90 
1419684_at Ccl8 chemokine (C-C motif) ligand 8 1.64 











Table C-3: Top 15 up- and down-regulated genes in TGF-β1 treated cells compared to 
control    
 
TGF vs SF Gene Gene description 
Log2 
ratio 
1419728_at Cxcl5 chemokine (C-X-C motif) ligand 5 -6.69 
1457871_at Colec10 collectin sub-family member 10 -6.35 
1449280_at Esm1 endothelial cell-specific molecule 1 -5.78 
1451798_at Il1rn interleukin 1 receptor antagonist -4.83 
1459636_at Angpt2 angiopoietin 2 -4.53 
1422651_at Adipoq adiponectin, C1Q and collagen domain containing -4.23 
1448152_at Igf2 insulin-like growth factor 2 -4.22 
1437932_a_at Cldn1 claudin 1 -4.04 
1448162_at Vcam1 vascular cell adhesion molecule 1 -3.93 
1419209_at Cxcl1 chemokine (C-X-C motif) ligand 1 -3.92 
1450928_at Id4 inhibitor of DNA binding 4 -2.99 
1426152_a_at Kitl kit ligand -2.95 
1420380_at Ccl2 chemokine (C-C motif) ligand 2 -2.95 
1450759_at Bmp6 bone morphogenetic protein 6 -2.92 
1418294_at Epb4.1l4b erythrocyte protein band 4.1-like 4b -2.89 
1423606_at Postn periostin, osteoblast specific factor 6.72 
1415978_at Tubb3 tubulin, beta 3 6.05 
1449169_at Has2 hyaluronan synthase 2 5.47 
1459994_x_at Trfr2 transferrin receptor 2 4.91 
1439604_at Adamts16 
a disintegrin-like and metallopeptidase  with 
thrombospondin type 1 motif, 16 
4.44 
1416342_at Tnc Tenascin C 4.36 
1421385_a_at Myo7a myosin VIIA 4.26 
1436978_at Wnt9a wingless-type MMTV integration site 9A 4.24 
1452968_at Cthrc1 collagen triple helix repeat containing 1 4.22 
1422812_at Cxcr6 chemokine (C-X-C motif) receptor 6 4.22 
1419613_at Col7a1 collagen, type VII, alpha 1 4.08 
1422125_at Htr2b 5-hydroxytryptamine (serotonin) receptor 2B 4.00 
1418350_at Hbegf heparin-binding EGF-like growth factor 3.96 
1425789_s_at Anxa8 annexin A8 3.93 
1435994_at Kcnh1 
potassium voltage-gated channel, subfamily H (eag-











Table C-4: Top 15 up- and down-regulated genes in combination of PDGF and TGF-β1 
treated cells compared to control    
PDGF+TGF vs 
SF 
Gene Gene description 
Log2 
ratio 
1457871_at Colec10 collectin sub-family member 10 -7.12 
1419728_at Cxcl5 chemokine (C-X-C motif) ligand 5 -6.60 
1449280_at Esm1 endothelial cell-specific molecule 1 -5.15 
1448152_at Igf2 insulin-like growth factor 2 -4.91 
1423017_a_at Il1rn interleukin 1 receptor antagonist -4.63 
1423954_at C3 complement component 3 -4.56 
1459636_at Angpt2 angiopoietin 2 -4.51 
1422651_at Adipoq adiponectin, C1Q and collagen domain containing -4.45 
1448162_at Vcam1 vascular cell adhesion molecule 1 -4.43 
1425663_at Il1rn interleukin 1 receptor antagonist -4.41 
1427313_at Ptgir prostaglandin I receptor (IP) -4.19 
1437932_a_at Cldn1 claudin 1 -4.08 
1420693_at Myom1 myomesin 1 -4.03 
1418745_at Omd osteomodulin -3.89 
1457644_s_at Cxcl1 chemokine (C-X-C motif) ligand 1 -3.72 
1423606_at Postn periostin, osteoblast specific factor 6.58 
1415978_at Tubb3 tubulin, beta 3 6.51 
1449169_at Has2 hyaluronan synthase 2 6.47 
1416342_at Tnc Tenascin C 4.91 
1422812_at Cxcr6 chemokine (C-X-C motif) receptor 6 4.86 
1459994_x_at Trfr2 transferrin receptor 2 4.55 
1422125_at Htr2b 5-hydroxytryptamine (serotonin) receptor 2B 4.53 
1421385_a_at Myo7a myosin VIIA 4.46 
1452968_at Cthrc1 collagen triple helix repeat containing 1 4.37 
1436978_at Wnt9a wingless-type MMTV integration site 9A 4.28 
1419613_at Col7a1 collagen, type VII, alpha 1 4.26 
1418350_at Hbegf heparin-binding EGF-like growth factor 4.21 
1423635_at Bmp2 bone morphogenetic protein 2 4.10 
1425789_s_at Anxa8 annexin A8 4.08 
1449824_at Prg4 
proteoglycan 4 (megakaryocyte stimulating factor, 
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